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ABSTRACT
Insulin stimulates glucose transport into skeletal muscle upon
binding to its cell surface receptor.

The signals which stimulate

transport are unknown. Studies of insulin's effects on muscle cell lines
and adipocytes suggest that increases in sn-l,2-diacyglycerol (DAG)
content may mediate insulin-stimulated glucose transport. To test
this, the effect of insulin on muscle DAG content was measured. DAG
increased in diaphragm and soleus muscles exposed to insulin in vitro
and in diaphragm in vivo. However, the supraphysiologic insulin dose
(60 nM) and incubation time required (10 min) are not consistent with
a role for DAG as a mediator of insulin stimulated glucose transport
(which is activated within 2.5 min in isolated muscle cells and by 0.6
nM insulin in intact muscle in vitro).
There is evidence that individual chemical speCIes of DAG may
provide a more specific signal. The DAG fraction from muscle was
resolved into 5 peaks by gas chromatography.

The species associated

with these peaks were identified by comparing their retention times to
those of standards . None of the species increased in response to 5 min
incubation with insulin; 2 species increased after 10 min; 4 after 20
min. These changes paralleled insulin-stimulated increases in total
DAG mass.
To distinguish between insulin-stimulated phospholipase catalyzed
hydrolysis of membrane phospholipids and insulin-stimulated de novo
synthesis of DAG, phosphatidylcholine hydrolysis and glucose flux into
lipids was measured. Insulin had no effect on the content of choline or

phosphocholine, which suggests that phosphatidylcholine hydrolysis in
muscle is not induced by insulin.

Insulin did, however, promote

glucose flux into DAG. Flux into total lipids also increased.
These data suggest that the insulin-stimulated increment in total
DAG mass in skeletal muscle is a downstream effect of insulinstimulated glucose transport and metabolism and therefore appears
not to be involved in mediating insulin-stimulated glucose transport.

Chapter 1

Literature Review

When blood glucose increases after a meal, insulin is secreted by
the pancreas. In response to insulin, muscle and adipose tissue remove
glucose from the blood either for immediate energy needs or for
storage. As the blood glucose level is eventually reduced, serum insulin
concentration decreases and rate of glucose transport returns to basal
levels. A broad body of evidence supports the theory that insulin's
effects, including glucose transport stimulation, are initiated upon the
binding of the hormone to its plasma membrane-bound receptor.
Beyond this initial event, little is known of the mechanisms which
transmit information from the activated receptor to the stimulation of
glucose transport.

This introductory chapter will describe current

models of insulin signaling and glucose transport. Also, since the role
of lipid mediators in insulin signaling will be examined in subsequent
chapters, lipid metabolism and its regulation will be described in this
chapter.
I.

Insulin receptor

Because of the central role of the insulin

receptor in the various actions of insulin, its biochemistry, including
ligand binding, structure and transmembrane signal transduction will
be reviewed.
A. Ligand-Binding characteristics

The hallmarks of a hormone

receptor include specific, high-affinity, saturable binding of its
autologous ligand and the ability to initiate the characteristic effects of
the hormone in its target cells. Insulin-insulin receptor binding
specificity was determined by the ability of unlabeled ligand to compete
with radiolabeled ligand for receptor binding. Unlabeled insulin
competes with 125I-insulin for insulin receptor binding in a dose and
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temperature dependent manner (1). Other hormones such as human
growth hormone, corticotropin or glucagon did not compete with
labeled insulin. Freychet et ale (1) also demonstrated that insulin
binding to cell surface receptors is saturable. Specific binding reached
a plateau as the molar ratio of insulin to insulin receptor was
increased. Furthermore, receptor affinity for insulin (Kd

= -3nM)

(2)

is sufficient to account for receptor activation under physiological
insulin concentrations of -O.lnM. Thus, insulin binds specifically and
with high affinity to a protein expressed on the plasma membrane of
insulin target tissues.

B. Insulin Receptor Structure

In 1972, Cuatrecasas isolated intact

insulin receptors from hepatocytes (3). Since then the protein structure
has been studied extensively (reviewed in (4, 5». The receptor is a
membrane bound glycoprotein of 350 kDa, consisting of two ex subunits
and two f3-subunits disulfide bonded in a

~-(X-(X-f3

subunits are 135 kDa and the

~-subunits

cDNA showed that the a and

~

confonnation. The (X-

are 95 kDa. Cloning of the

subunits are translated as a single

polypeptide of 180 kDa. The peptide is synthesized on ribosomes in the
endoplasmic reticulum (ER), cleaved and glycosylated in subsequent
steps in the ER and Golgi complex. The mature form is assembled and
exported to the plasma membrane (4).
The insulin receptor is a membrane spanning protein (Fig. 1); a
characteristic it shares with other peptide hormone receptors. This
topology was first suggested when it was found that the receptor is
only soluble in buffers which contain detergent (3). The hydropathy
plot of the amino acid sequence is consistent with the proposed
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topology (6). The membrane orientation of the insulin receptor was
studied using membrane-impermeant iodination reagents and 125 1. It
was found that insulin receptor a-subunits were iodinated when the
intact receptor was expressed in right-side-out vesicles but not insideout vesicles (7).

~-subunits

were iodinated in either orientation. These

data suggest that a-subunits are wholly extracellular while J3-subunits
span the membrane and have intracellular and extracellular domains.
Analysis of the amino acid sequence suggests that the receptor passes
through the membrane only once and the l3-subunit has a large (403
amino acid) cytoplasmic domain.

C. Insulin Receptor Function

The insulin receptor comprises

several functional domains. The a-subunits form the insulin-binding
domain. Binding to a-subunits was demonstrated by incubation of
intact receptors with 1251-1abeled insulin followed by addition of
chemical cross-linking reagents (8). When subunits were separated by
gel electrophoresis after disulfide bond reduction, radioactivity was
associated only with a-subunits.
Three J3-subunit functional domains have been identified. They are
the tyrosine kinase domain, the substrate residues for the receptor
tyrosine kinase and the hydrophobic membrane spanning domain.
These were identified by comparing the J3-subunit peptide sequence
with that of the epidermal growth factor (EGF) receptor which was
known at the time to be a transmembrane, ligand-activated tyrosine
kinase (reviewed in (9» and have been verified by studies of insulin
receptor mutations. Furthermore, the location of the domains involved
in phosphorylation was determined by loss-of-function studies of
specifically mutated receptors. Other domains which have been
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suggested to reside in the cytoplasmic portion of the receptor include
those for G-protein and phospholipase interaction (5). The possible
roles of such interactions are discussed below.
The sequence of the J3-subunit membrane spanning domain appears
to be nonspecific because insulin receptor function is largely
maintained if the transmembrane domains of other proteins are
inserted in place of the insulin receptor transmembrane domain (10).
Since insulin activates intracellular events without entering the
cell, this implies that the receptor transmit insulin's signal across the
membrane. Accumulated evidence strongly suggests that before irlsulin
binds, membrane-bound receptors are in a low phosphorylation state.
Seryl (Ser) and threonyl (Thr) residues account for most of the basal
phosphorylation; there is little (11) or no (12) tyrosine phosphorylation.
After insulin binds, several J3-subunit tyrosyl residues become
phosphorylated and the tyrosine kinase activity increases. Studies of
insulin receptors with tyrosine to phenylalanine substitutions indicate
that the phosphorylation of several tyrosines is important in receptor
activation (13). Autophosphorylation and activation of the tyrosine
kinase toward exogenous substrates appear to be the initial
intracellular events in insulin signaling. Several substrates of the
tyrosine kinase have been identified. Although their physiological
relevance remains unclear, the role of a few of them is slowly being
elucidated. They will be discussed below. The conformational changes
in the

(l-

and J3-subunits, which are presumably induced by insulin

binding and which subsequently transmit insulin's signal across the
plasma membrane, are unknown.
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The dose response of the insulin receptor tyrosine kinase to insulin
varies somewhat, depending on the tissue source of the receptor.
Insulin induces half-maximal autophosphorylation in Fao cells at -10
nM and a maximal effect at 100 nM (14). The dose required for halfmaximal response of muscle-derived receptors is -1 nM (15). These
concentrations are similar to the range of insulin levels ( . . . 0.4-0.6 nM)
attained in response to elevated plasma glucose.
The structure and function of the insulin receptor indicate that it
has similarities with other tyrosine kinase growth factor receptors
(EGF, colony stimulating factor-I) and cellular protooncogene products
(c-src). It is evident that their functions differ; the similarities,
however, have been useful in constructing testable hypotheses about
insulin-activated second messenger systems.
Although most physiological effects of insulin are thought to be
initiated by the insulin receptor tyrosine kinase activity, other
mechanisms for transmitting the insulin signal across the plasma
membrane have been proposed. For example, insulin binding induces
microaggregation of activated receptors in the plasma membrane (16).
It has been suggested that anti-insulin receptor antibodies mimic
insulin action by inducing receptor aggregation in the membrane (17).
Since insulin is thought to have only one receptor binding site it
apparently does not promote aggregation by forming a crossbridge
between receptors. An alternative explanatioll is that aggregation is
induced by the interaction of the insulin receptor cytoplasmic domains.
Butte has suggested that such interactions are regulated by
phosphorylation (18).
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II. Glucose transport

The movement of glucose across the plasma

membrane of most tissues is mediated by membrane-bound facilitative
transport proteins. Recently, five different transporter isoforms have
been identified and cloned in rats and humans (19). They are called
GLUT-l to GLUT-5 for the order in which they were cloned (19). Each
of the GLUTs transports D-glucose and not L-glucose and is saturable.
Cytochalasin B specifically inhibits facilitative glucose transport and
has been shown to bind to each of the GLUTs, thereby further verifying
their identity.
The primary structures of the five proteins have 50-90% horrlology
to each other (20). The sequences are most divergent in their
cytoplasmic domains. The five isoforms each have a characteristic
tissue distribution. GLUT-1 is found in most tissues including muscle
and adipose. GLUT-2 is expressed in the liver and the endocrine
pancreas. GLUT-3 is expressed in brain, placenta and kidney. GLUT-4
expression is restricted to muscle and adipose cells. GLUT-5 is found in
the small intestine. The Km of each isoform for glucose is in the
physiologic range and the variations among them are thought to reflect
individual tissue requirements for glucose.
Each GLUT isoform has 12 membrane spanning segments (20). A
large cytoplasmic loop between membrane spanning domains 6 and 7 is
also common to each. Their extracellular domains are glycosylated in
isoform-specific and tissue-specific patterns. The effect of glycosylation
on glucose transport or regulation is unclear.
Insulin stimulates glucose transport in skeletal muscle and
adipocytes by increasing the Vmax for transport. In 1980 Suzuki and
Kono (21) and Cushman and Wardzala (22), in independent studies,
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reported that insulin treatment of adipocytes stimulated the
translocation of glucose transporters from an intracellular membrane
fraction to a plasma membrane fraction. After GLUT-4 was identified
it was shown to be the predominant isoform translocated in response to
insulin (23). The mechanism which leads to enrichment of plasma
membrane GLUT-4 in response to insulin is unclear.

In the basal

state, GLUT-4 is almost completely sequestered in cytoplasmic
vesicles. These vesicles appear to be specialized aspects of the transGolgi reticulum (24). In adipocytes, GLUT-4 vesicles are found near
the plasma membrane. In muscle, the GLUT-4 vesicles are diffusely
distributed throughout the cytoplasm. Upon insulin stimulation,
GLUT-4 vesicles fuse with the plasma membrane and the total glucose
transport activity of the cell increases 10-40 fold in adipocytes and 2-5
fold in skeletal muscle (23). As the insulin signal is terminated, GLUT4 is resequestered into cytoplasmic vesicles, possibly by a mechanism
which resembles endocytosis (25).
An important and still controversial aspect of the model is whether

translocation alone is sufficient to account for the insulin-stimulated
increment in glucose transport. Translocation has been reported to be
sufficient by some laboratories but not by others. Calderhead and
Lienhard (26) found only 2-4 fold increase in plasma membraneassociated GLUT-4 protein in 3T3-Ll adipocytes, while glucose
transport increased IO-fold. They propose that an increase in GLUT-4
intrinsic activity accompanies the effect of insulin on translocation.
However, in rat adipocytes Slot et al. reported that plasma membrane
GLUT-4 increased 40-fold in response to insulin which was similar to
the insulin effect on glucose transport (27).
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GLUT-l is found largely in the plasma membrane of muscle in the
basal state. The sm.all am.ount of GLUT-l in the cytoplasm. is
maintained in a separate vesicle population and translocates to the
plasma membrane in response to insulin (28).
Although the effect of insulin on GLUT-4 intrinsic activity is
unclear, there is evidence that the intrinsic activity of GLUT-4
decreases in response to insulin counter-regulatory hormones such as
epinephrine (29) and isoproterenol (30). These agents, which are
known to inhibit glucose transport, have been suggested to decrease
the activity of GLUT-4 by promoting phosphorylation of specific
residues. These data suggest that the intrinsic activity is susceptible to
regulation by covalent modification.
The mechanism of insulin-stimulated glucose transport in skeletal
muscle appears to be similar to that in adipocytes but is less well
understood. GLUT-4 translocation to the plasma membrane in
response to insulin in muscle was suggested by membrane
fractionation studies (31). Since pure muscle membrane fractions are
difficult to prepare it is important that the immunohistochemistry
studies which have been reported also indicate that insulin induces
GLUT-4 translocation. Rodnick et at (24) used imm.unogold labeling of
GLUT-4 in thin sections of muscle to localize the transporter in basal
and insulin-stimulated muscle. In basal muscle, the gold particles
labeled small, cytoplasmic membrane structures and the trans face of
the Golgi apparatus. Few gold particles were found associated with the
plasma membrane. Upon insulin stimulation they found increased
labeling of the plasma membrane and a reduction of GLUT-4 protein
associated with isolated intracellular vesicles.
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Two other mechanisms of insulin-stimulated translocation of
GLUT-4 have recently been proposed. First, Smith et al. (32) have
reported that GLUT-4 is sequestered in membrane invaginations
instead of in distinct cytoplasmic vesicles. They suggest that insulin
may de-inhibit the lateral diffusion of GLUT 4 out of these membrane
pockets. The distinct GLUT 4-containing vesicles described by other
groups, they suggest, are artifacts of the membrane isolation
procedures.
A second model of insulin-stimulated GLUT-4 translocation was
recently described by Jhun et al. (33). They propose that GLUT-4
cycles constitutively between the PM and the cytoplasm in rat white
adipocytes. In this model insulin increases the equilibrium constant of
outward fluxes and decreases that for inward fluxes of GLUT-4 which
results in a net increase in plasma membrane-associated GLUT-4. The
almost complete absence of GLUT-4 immunogold labeling of muscle
plasma membranes reported by Rodnick et al. (24) suggests that this
mechanism is restricted to adipocytes.
GLUT-4 vesicle translocation resembles the later steps in the
protein synthesis pathway from the trans Golgi through secretion.
Transportation between stable ER and Golgi reticula is generally
thought to be mediated by the budding of small vesicles from the donor
compartment and subsequent fusion to the receiver compartment.
Studies of vesicle-mediated transport between ER and Golgi
compartments has also begun to elucidate mechanisms which may
regulate vesicle targeting and fusion. A cell-free system which uses the
compartment-specific glycosylation of a viral protein (vesicular
stomatitis virus G-protein) as a marker for transit has been
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established by Balch et al. (34). Using this system, Rothman and Orci
(35) have described a multi-subunit protein complex which forms
transiently to promote fusion of vesicles to acceptor compartments.
After fusion occurs, the complex disassembles. It may be hypothesized
that such a system, regulated by phosphorylation, regulates GLUT-4
vesicle fusion to the plasma membrane. Since such a protein complex
would necessarily be transient, its detection may require the
establishment of a cell-free system similar to that of Balch et ale (34).
There is evidence that small GTP-binding proteins are involved in the
regulation of these vesicles.

In this context it is significant that

Rodnick et al. have found small GTP-binding proteins associated with
GLUT-4 vesicles (24).
Although there are similarities between GLUT-4 cycling and the
pathways of protein secretion, GLUT-4 cycling is thought to be
mediated by a specialized type of vesicle. This is supported by studies
of immunopurified GLUT-4-containing vesicles. The GLUT-4-specific
monoclonal antibody IF8 has been used to immunopurify GLUT-4
containing vesicles. GLUT-4 and GLUT-l are segregated in separate
vesicles (36). As isolated, the vesicles were free of detectable markers
for the plasma membrane, SR, mitochondria and other intracellular
membranes. The vesicles also did not contain IGF-II receptors which
are known to be recycled between the plasma membrane and the
endosomellysosome compartment.
Targeting of GLUT-4 vesicle to the plasma membrane and
subsequent membrane fusion are probably directed and mediated
through interactions of vesicle surface molecules with the plasma
membrane. The information required for the targeting of a protein for
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secretion or cellular compartmentation is thought to reside in the
structure of the protein itself. Two studies ofGLUT-4 have shown that
its intracellular localization is coded for in its sequence, but the
information which targets GLUT-4 vesicles to the plasma membrane in
response to insulin is apparently not intrinsic to the GLUT-4 structure.
Haney et ale showed that GLUT-4, when expressed in fibroblasts which
normally do not increase glucose transport in response to insulin, is not
translocated to the plasma membrane in response to insulin. This
suggests that the infonnation which targets GLUT-4 for translocation
is not intrinsic to its structure. They also found that GLUT-4 and
GLUT-l are segregated in separate vesicle populations indicating that
information for intracellular sorting is expressed in the transporter
structure (36). These data are consistent with the earlier observations
ofGLUT-4 and GLUT-l segregation in adipocytes (28).
Any complete model of insulin-induced GLUT-4 translocation
should include a mechanism for regulated membrane fusion. A
mechanism has been difficult to establish because the physics of
membrane fusion are poorly understood. Externally directed
membrane-bound proteins have been shown to be involved in
determining the specificity of fusion events between membrane bound
cellular compartments (37). Whether they also mediate the fusion
event per se is unknown. It seems reasonable that protein-protein
interactions would stearically hinder the close apposition required
before membranes can fuse. Membrane proteins may also block fusion
by maintaining stable spheres of hydration which are known to inhibit
fusion. In the light of this, it has been proposed that fusion events are
initiated by the unmasking of non-polar domains of surface proteins. It
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IS

interesting, in the context of insulin action and its proposed

mechanisms of kinase and phosphatase activation, that membrane
proteins which mediate fusion are regulated by phosphorylation (38).
Whether GLUT-4 vesicle-plasma membrane fusion is mediated by
protein-protein interactions is not known. However, lipids such as 1,2diacylglycerol (DAG) and lysophospholipids, which cause membrane
phase transitions, also increase membrane fusion in artificial systems
and therefore are potential mediators of fusion (39). Considering this,
it is interesting to note a

preliminary report that showed

phospholipase A2 activity (PLA2 ), which increases lysophospholipids in
the membrane, was associated with a transport-promoting fraction of
cells from gastric mucosa (40).

Thus, fusion may be facilitated by

locally-produced fusogenic lipids.

III.

Glyco~en

synthesis The major pathways of glucose utilization

in muscle are glycolysis and glycogen synthesis. In muscle and liver it
is predominantly incorporated into glycogen. The flux of glucose
through glycogen is closely regulated. Insulin activates glycogen
synthase (GS), the rate-limiting enzyme in glycogen synthesis, and
inhibits glycogen phosphorylase, which liberates glucose-1-phosphate
from glycogen. When glucose is required for muscle energy, counterregulatory hormones such as epinephrine signal the activation of
phosphorylase.
Since several aspects of the insulin regulated pathway leading to
glycogen synthesis have been described, it serves as an example of an
insulin second messenger system. It has been well understood for
several years that GS is found in two fonns. GS h is generally inactive
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and requires glucose-6-phosphate (G-6-P) as an allosteric activator
while GS a is active without G-6-P. Fischer and Krebs showed that GS
11

is less phosphorylated than GS h. Therefore, GS activation depends

upon a reduction of its phosphorylation state which could be mediated
by either stimulation of a phosphatase or inhibition of a kinase.
Cohen's group (41) has reported that insulin activates a glycogen
particle-bound form of protein phosphatase 1 (PP1G) which in turn
dephosphorylates

and activates GS. PPIG is itself activated by

phosphorylation. Cohen's group also described an insulin-stimulated
protein kinase (ISPK) which phosphorylates PP1G at a site which
regulates activity (41). The ISPK is apparently not a direct substrate of
the insulin receptor tyrosine kinase because protein phosphatase 2A, a
Ser/Thr specific phosphatase, inactivates it. Thus, insulin must
activate a cascade which includes a SerlThr kinase which is in turn
activated by a tyrosine kinase.

IV.

Second

messen~ers

proposed to mediate insulin action

Although insulin's effects on downstream effector systems e.g., glucose
transport

and

glycogen synthesis,

require insulin receptor

autophosphorylation and insulin receptor tyrosine kinase activation,
no specific constituent of a known insulin effector system has been
shown to be a substrate for the insulin receptor tyrosine kinase. This
has led to extensive efforts to identify mechanisms which mediate
insulin action. Several mechanisms which have been examined will be
discussed below.
A. Proposed intermediate signal transducers

Several recent

reports have greatly increased our understanding of signal
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transduction cascades initiated by tyrosine kinase growth factor
receptors.

Several of these pathways involve activation of the ras

protooncogene product p21ras. The insulin receptor appears also to
activate this system through tyrosine phosphorylation of a protein
termed insulin receptor substrate-l (IRS-I). IRS-l is a specific and
early substrate of the insulin receptor tyrosine kinase (42). Although
IRS-l

does

not appear to have catalytic activity,

tyrosine

phosphorylated IRS-l has been shown to bind proteins containing src
homology-2 domains. These proteins include phosphatidylinositol 3kinase (PI3K), which has been shown to be activated in resporJ.se to
insulin (43), and growth factor receptor bound protein-2 (44). Whether
PI3K mediates insulin action is unknown. Recent studies, however,
have shown that GRB2 may mediate insulin stimulation ofras activity.
Ras is a small guanine nucleotide binding protein which appears to
mediate the signals of several growth factor receptors. The mechanism
by which ras transduces signals is slowly emerging. Ras-GTP is the
"active" state and ras-GDP is inactive. Growth factors are thought to
work by promoting the release of GDP and the re-association of ras
with GTP. The activity of ras is self-limiting in that it has intrinsic
GTPase activity.

Genetic studies in Drosophila have identified a

protein called Son of Sevenless which is a guanine nucleotide exchange
factor. Two mammalian homologues, called mSOSl and mSOS2, have
recently been cloned (45). Interestingly, mSOS binds to GRB2 and
this complex binds to IRS-l in response to insulin in L6 myoblasts (46).
The interaction of the

GRB2-mSOS complex with tyrosine

phosphorylated IRS-l increases the ratio ofras-GTP to ras-GDP.

14

While there is substantial evidence that ras is involved in mitogen
activated signal transduction pathways, the mechanism through which
it transmits signals is unclear. Recent studies have shown that at
least part of its effects may be mediated by the protooncogene product
c-raf-l (47).

c-Raf-l is a ser/thr kinase that is activated by direct

interaction with ras-GTP. One of the substrates of c-raf-l kinase is
MAPKK. MAPKK is important because it phosphorylates MAPK on
both thr and tyr, which is required for activation (reviewed in 48).
MAPK is a proline directed ser/thr kinase with a broad range of
substrates. These include kinases which are thought to be upstream of
of MAPK such as MAPKK and c-raf-1, as well as proteins which are
thought to mediate effects more distal to MAPK such as PLA2, c-myc,
c-fos and c-jun (48).
These data indicate that insulin activates a kinase pathway, parts
of which may be activated by other mitogen receptors. The mechanism
through which insulin activation of this pathway is recognized as
distinct from stimulation by other receptors is unclear. Furthermore,
the mechanism through which this pathway may activate glucose
transport also remains unclear.

B. G-proteins There is also evidence that heterotrimeric guanine
nucleotide binding proteins (G-proteins) may be involved in regulating
glucose transport. G-proteins are a family of regulatory proteins which
mediate signals arriving from outside of the cell. The generic structure
of G-proteins consists of a.,{l and 'Y-subunits. The (3 and 'Y subunits form
a tightly bound complex. The a-subunit binds guanine nucleotides.
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The first G-proteins to be described regulate the levels of cAMP by
either stimulating (G s ) or inhibiting (Gi ) adenylate cyclase. Subsequent
studies have revealed G-proteins which regulate the activity of several
different enzymes or membrane transporters. Specific G-proteins have
been shown to activate PLC-f3 regulate potassium channels, and to
translate the information from a photon into a chemical signal in
retinal cells (reviewed in (49)).
G-proteins undergo receptor-activated cycles of association and

f3y complex. In the inactive state
the a-subunit is bound to GDP and complexed to f3y. When the GDPdissociation of the a-subunit and the

bound trimer associates with its specific, ligand-bound receptor, GTP is
exchanged for GDP and a-GTP dissociates and becomes active. This
active state is self-limiting, as is the case for ras, by the GTPase
activity of the a-subunit. The GDP-bound form reassociates with the

f3y dimer.
The involvement of G-proteins in insulin signaling has been
suggested by several studies. Rothenberg and Kahn (50) showed that
activated insulin receptors, in vitro, block the pertussis toxin catalyzed
ADP-ribosylation of G i - They speculated that insulin induced a
conformational change in G i such that pertussis toxin no longer
recognized it. Other evidence also suggests that G-proteins mediate
insulin action. For example, Baldini et al. (51) have studied adipocytes
permeabilized with Staphylococcus aureus a-toxin which were able to
increase glucose transport in response to insulin. When they incubated
the permeabilized cells with GDPyS, a nonhydrolyzable GTP analog,
there was an insulin-like increase in plasma membrane-associated

16

GLUT-4. They note that GDPyS may either induce GLUT-4
translocation or inhibit its re-sequestration.
While these data are consistent with a role for G-proteins as
modulators of insulin action, they do not indicate that G-proteins are
necessary is insulin signal transduction.
C. Ca 2 + and cAMP

Insulin regulation of cyclic AMP (cAMP) has

been studied in adipocytes because cAMP-dependent kinase (PKA) is
important in the regulation of lipolysis. Insulin inhibits lipolysis and
most evidence indicates that insulin lowers cAMP in adipose cells by
activating a phosphodiesterase. Since cAMP is lowered in response to
insulin (52), it is not thought to stimulate glucose transport. The cAMP
analog dibutyryl-cAMP (Bt2cAMP) has been shown to increase the
amount of GLUT-4 in adipocyte plasma membranes, while inhibiting
its intrinsic activity, possibly through activation of PKA (52).
Studies of the possible role of insulin-induced changes In
cytoplasmic Ca2+ concentration are more complex. Cytoplasmic Ca2+ in
muscle is difficult to measure because fluorescent indicators of
cytoplasmic Ca 2+ concentration have not been used in intact skeletal
muscle. Similar studies in adipocytes have shown that insulin does not
elevate cytoplasmic Ca2 + (53). Rattigan et al. (54) have shown that
perfusing

rat

cardiac

muscle

with

solutions

containing

supra physiologic Ca2+ concentrations increases glucose transport and
GLUT-4 translocation. However, Sowell et al. have shown that the
insulin effect on glucose transport in incubated muscle is not Ca2 +dependent (55).
D. Protein kinase C

Protein kinase's C are a related group of DAG-

activated, phospholipid-dependent, Ser/Thr-specific kinases.
17

PKC

activity is thought to mediate the signal of receptors which activate the
hydrolysis of inositol phospholipids by activation of specific
phospholipases (56). Ca2 +-dependent and Ca2 +-independent isozymes
have been described. The Ca2 +-dependent group has been more
thoroughly studied.
PKC

species are protein monomers

of -67-84kDa. They

phosphorylate the hydroxyl group of protein seryl and threonyl
residues in a wide variety of structural contexts. Although a consensus
sequence has not been identified (57) in vivo substrates tend to be
flanked by lysine or arginine.
In the quiescent state, PKC is inactive and found in the cytoplasm.
PKC activation appears to be initiated by the formation of a complex
between PKC and membrane phosphatidylserine.

When PLC is

activated in response to an agonist, DAG becomes available and binds
to the DAG/phorbol ester binding site on PKC. This binding leads to a
conformational shift in PKC which frees its active site from allosteric
self-inhibition . It has been reported that once the enzyme is activated
it becomes Ca2 +- and DAG-independent (58).
Many early studies of PKC activation used PKC translocation to the
plasma membrane as a measure of activation. However, more recent
studies indicate that translocation and activation are separate events
(58). Therefore, quantifying PKC activation requires the identification
of a specific endogenous substrate. A specific and sensitive cellular
PKC substrate called MARCKS (myristolated alanine-rich c-kinase
substrate) has been identified in several cell types. Phosphorylation of
MARCKS has been used to further define the role of PKC in signal
transduction (59) .
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Activation of PKC by DAG is very specific and sensitive. Studies
with several DAG analogs have suggested that the oxygens in the ester
bonds and the hydroxyl on the sn-3 carbon are all required. Also, only
sn-l,2-DAG will activate PKC; 1,3-DAG and sn-2,3-DAG are inactive
(60-62). In vitro studies have suggested that the fatty acyl composition
of DAG required for PKC activation is not specific. However, in vivo
studies have shown that PI-derived but not PC-derived DAG activates
PKC (63).

Although DAG is thought to be the predominant

physiological regulator of PKC activity, other lipids, including PIP 2 ,
oleic acid, lyso-phosphatidic acid and arachidonic acid have been shown
to activate the enzyme (64).
The stoichiometry of DAG-PKC interactions has been studied using
detergent micelles of defined composition have shown that only one
molecule of DAG is required to activate a single PKC molecule (64).
PKC has been suggested to be involved in the regulation of a wide
variety of cell activities including gene expression, membrane
transport and enzymes (56).
E. Regulation of Phospholipase C

PLC activity is found in a

variety of proteins with different activation modes and substrate
specificities. They can be divided among phosphatidylinositol (PI)specific and phosphatidylcholine (PC)-specific activities. The PI-specific
enzymes comprise four subtypes termed (X,(3,"{ and
hydrolyze

PI,

phosphatidylinositol-4-phosphate

o.

They each
(PIP)

and

phosphatidylinositol-4,5-bisphosphate (PIP2) and require Ca2 + for
catalytic activity (65). The genes encoding the (3- and ,,{-subtypes have
been cloned and sequenced (66).
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The y and l3 PLC subtypes appear to be regulated by specific
interactions with tyrosine kinases and G-proteins, respectively. For
example, PLC-yl activity increases in response to activated EGF
receptors. PLC-yl has src homology-2 and -3 (SH2 and SH3) domains
(65). SH2 domains bind protein phosphotyrosine residues. SH3
domains bind to cytoskeletal elements (67). Upon activation and
tyrosine autophosphorylation of the EGF receptor, PLC-yl is thought
to bind the receptor tyrosine kinase residues through its SH2 domain.
This binding is thought to facilitate tyrosine phosphorylation and
subsequent activation of PLC-yl. It has been proposed that
phosphorylation induces a change in conformation which allows SH3
binding to the cytoskeleton, thus localizing the enzyme near the
membrane and its source of substrate. Whether similar activity is
induced by the insulin receptor is unknown. PLC-y may also interact
directly with the insulin receptor through binding to phosphotyrosine.
PLC-l3 isozymes appear to be linked to receptor activation by Gproteins. Recently, two related Ga isomers, a q and all, were reported
to activate PLC f3l-catalyzed hydrolysis of PIP 2 (68). When Ml
muscarinic cholinergic receptors and Gaq/ll were expressed in PLC f3containing lipid vesicles, Ml agonists-stimulated PLC activity (68).
Many agonists which increase DAG mass induce a multiphasic
DAG response. A rapid and transient increase in DAG is followed by a
slower and more prolonged increase. Studies using several
independent methods support the theory that the rapid increase is due
to phosphoinositide hydrolysis and the second phase of DAG is from PC
hydrolysis catalyzed by a PC-specific PLC (65). PC-specific PLCs have
recently been described in many cell types. The mode of activation and
20

the products of these enzymes suggests that their physiologic role is
different from. that ofPI-PLC.
PC and PI have different fatty acid profiles (69-71). Accordingly, the
DAG species produced by PC- and PI-PLC's are different. The
characteristic fatty acid profiles have been used to determine whether
PI- or PC-specific PLC is activated in response to a ligand. For the
most part, PC is rich in oleic and linoleic acid while PI species contain
:more arachidonic acid. Based on this characteristic, it has been
reported that vasopressin activates PC-PLC in hepatocytes (72).
The second phase of increased DAG mass appears to be stimulated
by the increase in DAG mass due to the earlier stimulation of PI-PLC
(73). Since PC-PLC is also activated by TPA (73) these data suggest
that in some systems, PC-PLC is activated by PKC. There are,
however, syste:ms in which PC hydrolysis is independent of PI
hydrolysis, e.g. EGF-induced PC hydrolysis in IIC-9 cells (72).
Other evidence of PC-derived DAG includes the agonist-induced
release of phosphocholine or choline from [3H]choline-Iabeled cells. PC
can be hydrolyzed to DAG directly by PLC or by the sequential activity
of phospholipase D (PLD) and phosphatidic acid phosphatase (PAP)
(yielding phospho choline and choline, respectively).
Agonist-stimulated PC hydrolysis and the consequent prolonged
increase in DAG mass may provide a different sort of signal than the
smaller transient activation from PI hydrolysis. For exaInple, since PIderived DAG is a source of arachidonic acid for prostaglandin
synthesis, and phosphatidylcholine is low in arachidonic acid, PCderived DAG Inay be a mechanism for separating DAG-induced signals
from the arachidonic acid cascade. Furthermore, the hydrolysis of PC
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does not increase the IP g concentration and should therefore allow
dissociation of the Ca2 + effect from the increase in DAG.

v.

DAG metabolism SN-l,2-diacylglycerol (DAG) is a neutral

glycerolipid constituent of cell membranes. Its generation in response
to receptor activation is a result of the hydrolytic removal of
phosphorylated headgroups of membrane phospholipids as discussed
above. DAG is also a metabolite of the phospholipid de novo synthesis
pathway (Fig. 2). Several lines of evidence indicate that the de novo
synthesis of DAG may be due to increased substrate availability which
in turn is due to increased metabolic flux. Also, lipid synthesis enzymes
may be regulated by covalent modification. Insulin may have an effect
on each of the mechanisms. Therefore, to establish whether DAG is an
insulin mediator, insulin's effects on DAG synthesis that result from
increased glucose transport must be distinguished from DAG that is
generated by phospholipid hydrolysis.
The immediate precursor of DAG in the phospholipid synthesis
pathway is phosphatidic acid (PA). Dihydroxyacetone phosphate from
glycolysis is reduced to glycerol-3-phosphate (by glycerol-3-phosphate
dehydrogenase) and then fatty acylated at the sn-l and sn-2 carbons.
These reactions are catalyzed by glycerol-3-phosphate acyltransferase
(G3PAT) and lysophosphatidic acid (LPA) acyltransferase, respectively.
The mechanism through which G3PAT is regulated is unclear. It has
been suggested that a pertussis toxin-insensitive G-protein may
activate G3PAT in BC3H-l myocytes (74). LPA acyltransferase from
parotid glands appears to be activated in vivo by agents which increase
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its phosphorylation, and in vitro by incubation with cAMP-dependent
kinase (75).
Whereas the glycerol moiety of glycerolipids are synthesized in
muscle, most of the fatty acids are taken up from the blood (76).
Phosphatidic acid phosphatase converts phosphatidic acid to DAG.
Currently, neither the mechanisms which regulate this enzyme or the
role it plays in lipid homeostasis are known. In at least two different
systems it appears to be regulated by product (DAG) inhibition (77,
78).

DAG is metabolized through the lipid synthesis and scavenger
pathways or by lipolytic enzymes. In cultured cells, DAG is
predominantly incorporated into phospholipids and TAG. The DAG
which is incorporated into phospholipids is mostly incorporated into
phosphatidylcholine (PC) (79). The first and rate-limiting step in the
PC synthetic pathway is catalyzed by cytidylyltransferase (CT). CT
catalyzes the synthesis of CDP-choline, the headgroup donor in
phosphatidylcholine synthesis. The activity of this enzyme appears to
be regulated by its subcellular location and by phosphorylation. In the
inactive state, it is found mostly in its phosphorylated form in the
cytoplasm. The active form of the enzyme has a lower phosphorylation
state and is associated with the plasma membrane fraction (80). This is
based on results showing that the Ser/Thr phosphatase inhibitor
okadaic acid inhibits CT activity by increasing the amount of enzyme
in the cytosol, where it is inactive (80). Translocation to the plasma
membrane and activation have been shown to be promoted by DAG
(81). This action of DAG is apparently PKC-independent, as shown by
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the dissociation between PKC activation and DAG-stimulated CT in a
neuroblastoma cell line (85).
DAG

is

also

a

precursor

of the

anIonIC

phospholipids

phosphatidylethanolamine (PE) and phosphatidylserine (PS). PE is
synthesized from the transfer of phosphoethanolamine,

to the

hydroxyl group of DAG. The headgroup donor in these transfer
reactions is

CDP-ethanolamine.

Phosphatidylserine

(PS),

is

synthesized by the exchange of serine for choline on PC. Furthermore,
the headgroups of PE and PS are interchangeable; PC can be
synthesized by the addition of three methyl groups from Sadenosylmethionine to the amino group ofPE.
Phosphatidylinositol (PI) synthesis is a minor pathway and PI is
usually 1-3% of cell phospholipids. The first step in the synthesis of PI
from DAG is phosphorylation of the primary hydroxyl group which is
catalyzed by DAG kinase (DGK). Isoforms of DGK are found in most
cell types. The regulatory mechanism of DGK is slowly being
elucidated.

Activation may require translocation to the membrane

which has been shown to be induced by DAG (82). Translocationinduced activation would be consistent with the enzyme's requirement
for PS and the physical requirement to be near its substrate.
Triglycerides are synthesized from DAG by the fatty acylation of
the primary hydroxyl group on the sn-3 carbon. This activity is also
increased in response to agents which activate cAMP-dependent
kinase. PKC in vitro does not activate the enzyme (75).
Since ras has been suggested to act as an insulin mediator, it is
interesting that ras also has been shown to regulate PC metabolism.
Pulse-chase labeling studies of choline metabolites in a fibroblast cell
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line transfected with activated H-ras demonstrated increased turnover
of PC compared to the native control (83, 84).

VI. Muscle-specific aspects of silmalin". Second messenger studies
of intact skeletal muscle are difficult compared to studies of cultured
cells (e.g., adipocytes). However, there have been reports which show
that the constituents of the IRS-l/GRB2-mSOS/ras pathway are
expressed in muscle (85, 86, 87). However, as with adipocytes, there is
no evidence that these molecules mediate insulin-stimulated glucose
transport in muscle.
Another important consideration during studies designed to
examine the role of DAG in insulin action is the capacity of skeletal
muscle to rapidly increase its DAG content. Cleland et al. have shown
that electrical stimulation of rat skeletal muscle results in a rapid (3
min) increase in DAG content (69).

Although the mechanism of insulin-stimulated glucose transport in
skeletal muscle appears to be similar to that described in adipocytes
(i.e., receptor activation followed by translocation of GLUT4 to the
plasma membrane) the response of glucose transport to insulin in
muscle differs quantitatively. Whereas glucose transport is stimulated
>20 fold in adipocytes, the response in muscle is -3-5-fold.
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Figure 1-1 Schematic representation of the insulin
receptor
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Figure. 1-2

1,2-Diacylglycerol synthesis and downstream

metabolism. Dihydroxyacetone phosphate (DHAP), from glycolysis,
supplies the 3-carbon glycerol backbone of all glycerolipids. The
enzymes denoted by numerals are:
dehydrogenase;

2,

1, glycerol-3-phosphate

glycerol-3-phosphate

lysophosphatidic acid

acyl transferase;

3,

acyltransferase; 4, phosphatidic acid

phosphatase; 5, DAG kinase; 6, CDP-DAG synthase; 7, PI synthase; 8,
DAG acyltransferase; 9, triacylglycerol lipase; 10, choline kinase; 11,
CTP : choline cytidylyltransferase; 12, diacylglycerol : choline
phosphotransferase; 13, phosphatidylinositol-phospholipase C; 14,
phosphatidylcholine-phospholipase C. The hydrogen which is bound to
the hydroxyl group at position 5 of glucose is released as H 2 0 during
the enol isomerization between DHAP and glyceraldehyde-3phosphate. Phosphatidylcholine, phosphatidylethanolamine and
phosphatidylserine are readily interconvertible due to numerous
headgroup exchange and modification activities.
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Chapter 2

Does Insulin Increase sn-l,2-Diacylglycerol Mass in Rat Skeletal
Muscle?

Portions of this chapter have been published: Sowell, M. 0., K. P. Boggs, K. A.
Robinson, S. L. Dutton and M. G. Buse tlEffects of insulin and phospholipase
C in control and denervated rat skeletal muscle." Am. I. Physio!. 260; E247E256, 1991 and Boggs, K. P., Farese, R. V., and M. G. Huse. "Insulin
administration in vivo increases 1,2-diacylglycerol in rat skeletal muscle"
Endocrinology. 128; 636-8, 1991.

INTRODUCTION
GLUT-4, the insulin-responsive facilitative glucose transporter, is a
membrane-bound protein, found both in plasma membranes and in a
specific type of small membrane-bound vesicle. The distribution of
GLUT-4 between these fractions is regulated by insulin (1). In
unstimulated cells, most GLUT-4 protein is found associated with the
cytoplasmic vesicle fraction. In membrane fractions of insulin treated
adipocytes and muscle, there was a reduction in GLUT-4 associated
with the cytoplasmic vesicle fraction and a concomitant increase of
GLUT-4 in the plasma membrane fraction. The signal transduction
cascade that lies between the activated receptor and GLUT-4
translocation is unknown. Three mechanisms which have been studied
in some detail will be discussed here. None of them is a complete
paradigm accounting for all the known physiologic events initiated by
insulin. Therefore, evidence supporting any of them should not
necessarily be inconsistent with a role for the others in insulin
signaling. First, recently described insulin receptor tyrosine kinaseinitiated phosphorylation cascades are potential stimulators of glucose
transport. The mechanism envisioned, although not supported by
observations, involves changes in the phosphorylation state of GLUT-4
vesicle proteins or plasma membrane proteins. Such covalent
modification would subsequently promote specific recognition and
fusion of the vesicles to the plasma membrane. This kinase cascade is
described in Chapter 1. Second, GLUT-4 translocation may be induced
by lipids such as 1,2-diacylglycerol (DAG) which have been shown to
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promote membrane fusion (2).

Third, activation of PKC through

insulin-induced increases of DAG content has also been proposed to
stimulate glucose transport (3).

Diacylglycerol and membrane fusion

It is well known that cells

exert tight regulation over the flow of material between discreet
membrane-bound compartments. Such regulation ultimately depends
upon strictly limited membrane fusion. Limited fusion of membranes is
maintained by the charge repulsion between membranes and the
stable packing arrangement of the constituent lipids of membranes (4).
Therefore, for fusion to occur, charge repulsion must be overcome and
unstable lipid phases must be induced. DAG is a potential mediator of
vesicle-plasma membrane fusion because its incorporation into
membranes promotes the unstable lipid-packing phases which occur
during fusion. Indeed, DAG has been shown to stimulate the fusion of
artificial phospholipid vesicles (2).

DAG has also been shown to induce the translocation of several
cytosolic proteins (e.g. DAG kinase (5) and cytidylyltransferase (6) to
the plasma membrane. This suggests a mechanism for translocation
whereby DAG induces fusion of GLUT-4-containing vesicles by
interacting with a vesicle-surface protein.
Several recent reports suggest that increases in membrane DAG
content may stimulate glucose transport in skeletal muscle. Stralfors
has shown that glucose transport in adipocytes was stimulated by
incubation with DAG (7). Furthermore, phospholipase C (PLC), an
enzyme which increases cell DAG levels (8), stimulates glucose
transport in muscle (9, 10). There is also evidence that insulin
activates endogenous PI-PLC activity in adipocytes (11, 12) and
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hepatocytes as well as in plasma membranes isolated from Rat-l
fibroblasts which had been transfected with human insulin receptors
(13).

Protein kinase C When the work for this section was started, there
was evidence from experiments in muscle cell lines that insulin
increases glucose transport through the PKCIDAG system. To examine
the possible role of this system in insulin action, Farese's group
measured DAG mass and PKC localization in insulin-treated BC3H-l
myocytes (14). This cell line expresses insulin receptors and responds
to insulin by increasing glucose and amino acid transport (15). They
found that insulin induced a significant increase in DAG in these cells
and this response preceded the stimulation of glucose transport. They
also found that insulin induced the translocation of PKC to the plasma
membrane in these cells. The insulin dose response curve of DAG
content and PKC translocation overlapped that of glucose transport.
Taken together, these data suggest that DAG may mediate insulinstimulated glucose transport in muscle. They do not, however, indicate
whether DAG stimulates glucose transport through direct physical
effects on the plasma membrane or through PKC activation. A diagram
representing insulin-stimulated glucose transport and the proposed
roles of DAG as an insulin mediator is shown in Fig. 2-1.
To test whether DAG is a mediator of insulin-stimulated glucose
transport, the effect of insulin on the DAG content of skeletal muscle
was measured.
The maximal effects of PLC on glucose transport are less than the
maximal effects of insulin (10). To test whether the glucose transport
response is proportional to the increment in DAG released by PLC, the
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MATERIALS AND METHODS

Animals.

Male Wistar BR rats (Charles River Laboratories,

Wilmington, MA) were studied. The animals were routinely fasted
overnight before experiments were perfonned.
Muscle incubations. The rats were decapitated and the muscles to
be studied were rapidly removed. Solei were attached with surgical
clips to stainless-steel frames to maintain their resting length;
diaphragms were incubated attached to the rib cage. Muscles were
incubated individually in either Gey and Gey's bicarbonate-buffered
balanced salt solution (16) or in Dulbecco's modified Eagles medium
(DMEM). All buffers contained 0.1% bovine serum albumin and were
maintained at pH 7 . 4 and 37 °C by incubation in a rotating shaker
water bath and continuous gassing with 95%02-5%C02.
Glucose transport The uptake of 2-deoxyglucose (2-DG) was used
as a measure of glucose transport into muscle. Hemidiaphragms were
incubated 30 min in BSS without or with insulin at the concentrations
indicated. 2-DG transport was measured by transferring muscles to
identical media supplemented with 5.0 mM 2-[1,2· 3H]deoxyglucose (0.5
f..lCi/ml) and 0.1 mM [U_ 14 C]sucrose (0.1 )..lCi/ml; included as an
extracellular space marker) for 15 min. Mter this incubation, the
muscles are dissolved in 0.5 ml I.ON NaOH and then neutralized with
2 . 0 N HCI for quantitation by liquid scintillation spectrometry.
Transport of 2-DG was calculated after correction for counts in the
extracellular space .
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In vivo Experiments. Rats were anesthetized with methoxyflurane
(Metofane, Pittman-Moore, Washington Crossing, NJ) and were
injected via tail vein with insulin (50 mU/g) or with saline. To prevent
hypoglycemia, insulin-injected rats also received an intraperitoneal
injection of 0.3mL of glucose solution (44%, w/v); controls received
saline. Ten minutes after the injection, rats were decapitated and the
diaphragm muscles were rapidly dissected from the rib cage and
immediately frozen in liquid nitrogen. Trunk blood was collected for
serum glucose assays. Glucose was measured by a Beckman Glucose
Analyzer 2 (Beckman, Fullerton, CA).
Quantitation of DAG

Solei were preincubated 20 min and then

transferred into insulin-containing or control media for 10 min.
Diaphragms were preincubated 30 min (unless otherwise indicated).
Either the appropriate agents or vehicle were added or muscles were
transferred to media supplemented with the additions indicated and
the incubation was stopped after various times as described in the text
or figures. After incubation, solei were removed from frames or
diaphragms were dissected from the rib cage and rapidly frozen in
liquid N2 and frozen and ground to a fine powder. Weighed aliquots of

the powder were further disrupted and the lipids extracted by
homogenization with a Polytron in 5ml of chloroform-methanol (1:2,
vol/vol). To separate the phases, equal volumes of chlorofonn and water
(1.6 mL) were added. The aqueous phase was washed twice with
chloroform and the organic phases were pooled in 12 x 50 mm glass
tubes then dried and stored under N2- DAG in the samples was
measured by the DAG kinase assay which was adapted from previous
reports (17,18). The dried lipid extract was mixed with 7.5% octyl-f3-D-
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glucopyranoside and 5mM cardiolipin in ImM diethylenetriamine
pentaacetic acid. The samples were vortexed for 30 s, sonicated in a
water bath for 20 min, and mixed for 30 min on a platform shaker. The
micelle suspension was incubated with DAG kinase and y-[32P1ATP for
30 min to convert DAG into [32p]phosphatidic acid. The latter was

extracted with chloroform-methanol (2:1), dried under N 2 , separated on
silica gel 60 thin-layer chromatography (TLC) plates and localized by
autoradiography. The spots were scraped into glass vials, scintillation
fluid was added and the radioactivity was quantitated by liquid
scintillation spectrometry_ DAG was quantitated by comparison to
18:1-18:1 standards, assayed concurrently. A sample DAG standard

curve is shown in Fig. 2.
Materials Monocomponent crystalline pork insulin was a gift from
Dr. Ronald Chance, Eli Lilly Research Laboratories (Indianapolis. IN).
Chloroform and methanol were from EM Science.

Lipid standards

were from Serdary Research Laboratories (London, Ontario, Canada).
Radiolabeled compounds were from American Radiolabeled Chemicals
(St. Louis. MO). All other reagents were purchased from previously
identified sources (10).
Data presentation

Data are expressed as means ± SE of n

observations. Differences were tested by Student's t test, with
significance taken as p < 0.05.
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RESULTS
The insulin dose response of glucose transport in muscle is well
studied and is similar among the various muscle types which have
been examined . The half-maximal response was -0.6 nM (19).

To

verify that diaphragm responded in a similar fashion in our hands, the
effects of 0.6 and 6 nM insulin on glucose transport into diaphragm
was tested. The results in Fig. 3 show that at both doses insulin in
vitro increases glucose transport significantly.

To measure DAG mass, the DAG kinase assay was adapted for use
with muscle lipid extracts. The effect of PLC on muscle DAG content
was studied as a positive control. The results (Fig. 8, leftmost pair of
bars) show that PLC induced an increase in DAG mass of more than
100% over basal.
To assess the effect of insulin on muscle DAG mass, diaphragms
were incubated without or with insulin, lipids were extracted and DAG
mass was measured by the kinase assay. The results of an insulin dose
response study are shown in Fig. 4. In a 10 min incubation only the
highest dose studied (60 nM) increased the DAG mass significantly.
Glucose transport in isolated skeletal muscle cells was significantly
increased after 2.5 min incubation with insulin (20). Therefore, a time
course was performed. As shown in Fig. 5, there was no detectable
increase in DAG after 5 min of exposure to 60nM insulin. The effect at
10 and 20 min was significant and did not change during this interval.
The effect of insulin on DAG was also measured in soleus muscle in
vitro. Solei were preincubated in BSS supplemented with 2 mM
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pyruvate without additions for 20 min then transferred to identical
media without or with insulin (60 nM) for 10 min. Insulin induced a
small but significant (20% over basal, paired analysis) increase in total
DAG content (Fig. 6). Thus, the effect in diaphragm was not muscletype specific. Also, since BSS is glucose-free, this result suggests that
insulin's effect on DAG is not glucose dependent in this muscle. The
effect of glucose on insulin-stimulated DAG in diaphragm will be
discussed in Chapter 4.
The core of isolated muscle may become anoxic during incubation
(19). Since anoxia may effect metabolic pathways, the effect of insulin
in vivo on DAG mass in muscle was measured (21). Rats were injected
I.V. with insulin or with vehicle; DAG was extracted and measured by
the kinase assay. The insulin dose used has been shown to maximally
activate insulin receptors in vivo (22). As shown in Fig. 7, the DAG
content of diaphragm was -40% higher in insulin treated rats than in
the concurrently assayed controls. The increase in DAG was not
dependent on insulin-induced hypoglycemia since the latter was
prevented by the co-administration of glucose. (Plasma glucose in
control was 7.0 +/- 0.17; insulin-treated, 8.0 +/- 0.39 mM, mean +/- SE,
n=6.)

Since Ca 2 + is required for PLC to stimulate glucose transport in
vitro (9), the effect of Ca2 + on PLC-induced increases in DAG was
measured.
added

Soleus muscles were incubated in BSS, in BSS without

Ca 2 + (low Ca 2 +) or in media without added Ca 2 + but

supplemented with Mg2+ (6.3 mM versus 1.3 mM in normal BSS). As
reported by Sowell et ale (10), there was no effect of PLC on glucose
.transport in muscles incubated in low Ca2 + media. Insulin significantly
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increased glucose transport in muscle incubated in high Mg2+ buffer;
the response however was lower than that in Ca2 +-supplemented
media. As shown in Fig. 8, DAG content increased only 50% over basal
in low Ca2 + buffer compared to a greater than 100% increase in Ca2 +supplemented media. The data also show that elevated Mg2+ can
partly substitute for Ca2 +. The effect of PLC on DAG levels in high
Mg2+, low Ca2 +, was intermediate between that observed in low Ca2 +
media and standard media and was significantly different from both .
Although we and Farese's group have shown that insulin increases
DAG in muscle, the doses required, both in vitro and in vivo, are
supraphysiological (10, 21, 23). Insulin and insulin-like growth factor-l
(IGF-1) are structurally similar and cross-react with each others
receptors with approximately 1% affinity of the homologous ligand. The
IGF-l receptor also has tyrosine kinase activity and increases glucose
transport in hindlimb muscle with a dose response similar to insulin
(24, 25). Therefore, it was speculated that high doses of insulin may
increase DAG through activation of IGF-1 receptors. To test this,
diaphragm muscle was incubated with a physiological (6 nM) and a
supraphysiological (60 nM) dose ofIGF-l. There was no effect ofIGF-l
at either concentration (Fig. 2-9).
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DISCUSSION
The studies described in this section provided the first evidence
that insulin increases the DAG content of skeletal muscle (10). The
effect was seen in muscles exposed to insulin either in vitro or in vivo
(21). Also, the effect was not muscle-type specific since both diaphragm
and soleus muscle responded to insulin in vitro. Consistent with this,
work from Farese's lab has shown a similar effect in gastrocnemius
m.uscle in vivo (21).
Insulin

stimulates

glucose

transport

In

diaphragm

at

concentrations -100-fold lower (0.6 nM) than that required to increase
DAG mass. The response of DAG, though, was not seen below 60 nM
(Fig. 4). There was also a temporal discrepancy between insulinstimulated glucose transport and insulin-induced increases in DAG
levels;

glucose transport was increased in isolated skeletal muscle

cells as early as 2.5 min (20) while detectable changes in DAG required
10 min incubation (Fig. 5). Recently, Ishizuka et ale has shown that
DAG was increased in diaphragm after only 2 min exposure to 60nM
insulin (23). This time course is more consistent with the glucose
transport response to insulin. The apparent contradiction between our
results and those of Ishizuka et ale may be the result of differences in
the strain of rat studied or the size of the animals at the time of
experim.ents. Although the difference could be technical, this seems
unlikely because the DAG content and the -fold increase in response to
insulin at the later time points reported by both groups are similar.
These data do not support the hypothesis that DAG mediates
insulin's signal; they are not, however, incompatible with it. Insulin
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may elicit increases in DAG mass which are below the sensitivity of the
assay. Since insulin-induced changes in DAG content may be both an
early and transient signal, downstream amplification mediated by a
transduction cascade may render small increases in DAG sufficient to
stimulate glucose transport.
While this work was in progress, a report by Henriksen et ale (9)
suggested that the effect of PLC on glucose transport involved an
increase in cytoplasmic Ca2 +, based on the following observations:
dantrolene, which blocks Ca 2 + release from sarcoplasmic reticulum,
inhibits PLC-stimulated, but not insulin-stimulated, glucose transport
and the effect of PLC was dependent on incubation with Ca2 +containing medium. The requirement for Ca2 + is consistent with the
previously reported Ca 2 +-dependence of PLC (26). Our data confirm
and extend these observations. It was found that incubation with Ca2 +
was required for a maximal effect of PLC on DAG content and that
Mg2+ supports at least partial activity of PLC (Fig. 8). Comparison of
these results with the ion requirement of PLC-stimulated glucose
transport (10) suggests that the two effects of PLC have parallel ion
requirements.
However, the inhibition of PLC-stimulated glucose transport by
dantrolene does suggest that the PLC effect on glucose transport is
mediated by increased cytoplasmic Ca2 +. This appears to be in contrast
to the mechanism of insulin action. Sowell et ale has shown that insulin
stimulates glucose transport in media without added Ca2 +, to 80% of
its maximal effect in media with added Ca2 + (10). Also, dantrolene had
no significant effect on the -fold increase in glucose transport induced

by insulin (~ insulin). The different Ca2 + requirement of PLC- and
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insulin-stimulated glucose transport is not necessarily inconsistent
with a role for DAG in insulin action. The two agents almost certainly
increase DAG in different spatial and temporal patterns and these
differences may elicit distinct metabolic effects. Large increases in the
local concentration of DAG should have nonspecific effects due to
perturbations in membrane fluidity and structure. Smaller changes
should be expected to lead to more specific effects e.g., through its role
in PKC signaling. Other possible differences between the effect of PLC
and insulin treatment include the chemical species of DAG generated
in response to either treatment.
The results presented here appear at variance with in

VIVO

experiments by Turinsky et al. (27), who observed no change in DAG
content of rat calf muscles in response to intravenous bolus injection of
insulin (0.1 U 1240 g rat, -0.4mU/g). While this dose is 125-fold lower
than that used in our experiments, it increased the accumulation of 2deoxyglucose in muscle several-fold over a 25 min period. However,
more complete receptor activation by the higher insulin dose in our
experiment may account for the effect on DAG content. Consistent with
this, muscle has "spare" insulin receptors i.e., only a small fraction of
the insulin receptors needs to be activated for any given level of glucose
transport stimulation (28). For example, activation of the insulin
receptor tyrosine kinase activity in rat muscle was barely detectable 5
min after intravenous bolus injection of 0.5 mU/g insulin, a dose which
induces a maximal glucose transport response. A dose of 5 mU/g was
required for full receptor activation (28). Therefore, the DAG response
may only be detectable upon full activation of muscle insulin receptors.
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The

difficulties inherent in assessing changes in DAG

concentrations in response to in vivo stimuli are exemplified by
discrepant results from studies of the effects of muscle contractions.
Turinsky et al. did not observe an increase in DAG content in response
to exercise induced by electrical stimulation of calf muscles in vivo (27).
In contrast, Cleland et al. reported a 2-fold increase in both DAG
content and protein kinase C translocation within 2 min of initiating
muscle contractions by sciatic nerve stimulation in vivo (29).
A further difficulty in detecting insulin-induced increases in DAG
include the inability to measure plasma membrane DAG specifically.
Since the plasma membrane is the site of insulin receptor activation
and initiation of signal transduction as well as GLUT-4 translocation,
only changes in DAG in the plasma membrane should be
physiologically relevant. Therefore insulin-stimulated changes in DAG
mass at subcellular locations other than the plasma membrane would
artificially delay any apparent increase in plasma membrane DAG due
to the high background against which they are measured.
The studies of the effects of insulin and PLC on glucose transport
and DAG content presented here, revealed that the rate of glucose
transport is not always proportional to increased in DAG levels.
Whereas DAG increases 2-fold in response to PLC (Fig. 2-8), the PLC
effect on glucose transport was less than insulin's effect (10).
Considering these data, it can be hypothesized that a subpopulation of
DAGs or an subcellularly restricted pool of the lipid is the active factor
involved in stimulating glucose transport. It may be surmised that
such changes in species or local concentrations would be both transient
and insignificant compared to changes in total DAG mass .
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In summary, insulin doses which maximally activate glucose
transport (in vitro) or insulin receptors (in vivo) significantly increased
DAG content. A role for DAG as an insulin second messenger cannot,
however, be established from these data because this change in DAG
did not preceed the effect of insulin on glucose transport. The data do
lend support to the hypothesis that insulin may promote changes in
either subcellularly restricted pools of DAG or in structurally distinct
forms of DAG.
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Figure. 2-1 Proposed scheme of insulin-induced GLUT-4 vesicle
(GV) translocation in muscle and the potential role of DAG in the
system. Insulin binding may (mechanism 1) lead to the direct tyrosine
phosphorylation of a docking protein (D), or to an increase in DAG
mass (via phospholipase C (PLC) activation) (mechanism 2, 3), which
in turn may act through either activation of protein kinase C and the
subsequent phosphorylation of docking molecules (mechanism 2), or by
local changes in membrane fluidity (1\ fluidity; mechanism 3). GLUT-4
molecules are represented as pairs of filled ellipsoids.
phosphorylated serines or threonines, pY, phosphotyrosine.
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Figure. 2-2 A DAG kinase standard curve. Increasing amounts of a
DAG standard (18:1-18:1) were assayed in triplicate, as described in
Methods. The results are means +/-SE of 32p incorporated into
phosphatidic acid. Where the standard error bars are not visible they
are eclipsed by the graph symbol.
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20

Figure. 2-3 Effect of insulin on glucose transport in diaphragm
muscle.

Hemidiaphragms were preincubated 30 min in BSS without

(open bars) or with (filled bars) insulin at the doses listed. Uptake of 2deoxyglucose was measured in a subsequent 15 min assay as described
in Methods. The data are expressed as means +/- SE, n = 3 (0.6 nM) or
5 (6 nM).
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6

Figure. 2-4

Insulin dose response diaphragm DAG content.

Hemidiaphragms, attached to adjacent ribs, were preincubated in

DMEM without additions for 30 min. Insulin (filled bars; final
concentrations indicated) or vehicle were then added. Mter 10 min the
muscles were rinsed, rapidly excised from the rib cage, and frozen in
liquid nitrogen. DAG was extracted and measured as shown in

Methods. The data are means ± SE in nmol DAG/gram muscle, n = 4-6.
*, Insulin> Basal, p < 0.05.
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Figure. 2-5 Effect of insulin on DAG mass in hemidiaphragm
muscle. Muscles were preincubated 30 min in basal medium and then
vehicle (open bars) or insulin (final concentration 60 nM, filled bars)
was added. Muscles were frozen 5, 10 or 20 min later and DAG was
measured by the kinase assay as described in Methods. The data are
means ± SE of at least 6 observations. *, Basal < Insulin, p < 0.05.
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Fig. 2-5
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20 min

Figure. 2-6 Effect of insulin on DAG content of soleus muscles in

vitro. Solei were attached to metal frames and preincubated 20 min in
Gey and Gey's BSS (supplemented with 2 mM pyruvate and 0.1% BSA)

and then transferred to identical media without (open bar) or with
insulin (60 nM, filled bar) for 10 min. Muscles were then rapidly
removed from frames, frozen in liquid nitrogen and ground to a
powder. DAG was measured by the DAG kinase assay as described in

Methods. The data are means + SE of 6 observations. Insulin> Basal,
p < 0.05, paired analysis.
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Figure. 2-7 Effect of insulin in vivo on diaphragm muscle DAG
content. Overnight-fasted rats received an intravenous injection of
insulin (50 mU/g) or saline; insulin treated rats received an
intraperitoneal injection of glucose, controls received saline. Rats were
killed 10 min later and diaphragms were rapidly excised and frozen in
liquid nitrogen. Muscle DAG was measured by the DAG kinase assay
as described in Methods. The results are means ± SE of 6 observations.
*, Insulin> Basal, p < 0.05.
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Figure. 2-8 Cation requirement of PLC activity. Soleus muscles
attached to metal frames were preincubated in standard BSS (2.0 mM
Ca 2 +, 1.3 mM Mg2+) or in media with the indicated ion composition for
20 min then transferred to identical media without (open bars) or with

PLC (0.5 U/mL; filled bars) for 30 min. DAG was measured by the DAG
kinase assay as described in Methods. Values are means + SE,
(number of observations in parentheses). *, PLC > Basal, p < 0.01;
bars with same notation are significantly different, p < 0.01.
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Figure. 2-9 The effect of insulin-like growth factor-l (IGF-l) on
muscle DAG.

Hemidiaphragms attached to adjacent ribs were

preincubated in media without additions for 30 min. Vehicle (open
bars) or IGF-l (filled bars) was added to a final concentration of 6 nM
or 60 nM. Mter 10 min, the muscles were rinsed, cut from the ribs and
frozen in liquid nitrogen. DAG was extracted from the muscle and
measured by the DAG kinase assay as described in Methods. The data
are the means + SE, n = 4. There was no significant effect of IGF-l at
either dose.
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ChapterS
Does insulin increase an individual DAG species or specific
structural forms of DAG in rat skeletal muscle?

Portions of this chapter have been submitted for publication to The American
Journal of Physiology

INTRODUCTION

Insulin has pleiotropic effects on skeletal muscle which include
increasing glucose transport and glycogen synthesis. The signaling
mechanisms which activate these pathways are still not clearly
understood. Studies of insulin second messengers, by our group and
others, have shown that muscle 1,2-diacylglycerol (DAG) levels
increase following insulin treatment in vivo and in vitro (1-3).
However, these results have not been reproduced in other similar
studies (4). Therefore, the role of DAG in insulin signaling is still
unclear. To help define the role of DAG in this system, experiments to
further examine the response of DAG to insulin have been performed.
The initial studies on the role of DAG in insulin signaling indicated
two apparent discrepancies between the response of DAG and the
response of glucose transport to insulin. First, that an increase in the
total mass of DAG does not precede insulin's effect on glucose
transport (Chapter 2 and (3)). Second, the dose of insulin required to
increase DAG was -100-fold higher than that required to stimulate
glucose transport. The technological limitations which may have led to
this are discussed in the previous chapter. There are, however,
alternative explanations which seem logical in the light of other
evidence. Consider: The effect of PLC on glucose transport is less than
that of insulin (Chapter 2) although it induces a large (>100%) increase
in DAG mass (Chapter 2). Conversely, insulin increases glucose
transport -2-3-fold (Chapter 2 and (3)) but it has a relatively small
(30%) effect on DAG mass (Chapter 2). This disproportionate response
84

between DAG and glucose transport suggests that only a small fraction
of the DAG's generated by PLC may be active in stimulating glucose
transport.
DAGs are a group of chemically related glycerolipid species. They
consist of 2 fatty acids esterified to the stereoscopically numbered-l
(sn-l) and sn-2 carbons of glycerol. The fatty acids found in naturally
occurring DAGs differ in hydrocarbon chain length and degree of
uns aturati on. DAG species are denoted by the number of carbon atoms
and carbon-carbon double bonds of the fatty acids esterified to the sn-l
and sn-2 carbons of glycerol (e.g., 16:0-18:1009 has a 16 carbon fatty
acid with no carbon-carbon double bonds at the sn-l carbon and an 18
carbon fatty acid with one double bond between the ninth and tenth
carbons esterified to the sn-2 carbon). The fatty acid composition of
most naturally occurring DAG species is consistent with phospholipid
composition: the more unsaturated fatty acid is bound to the sn-2
carbon (5).
There are biological precedents of agonist-induced changes in
chemically-defined subgroups of DAG. For example, Pessin and Raben
have shown that a-thrombin stimulates a rapid and transient increase
in one group of DAG species at 15 sec while a different group increases
more slowly and the response is more sustained. The fatty acid
composition of the DAG found during the early response suggests that
they are derived from hydrolysis of phosphoinositides; the source of the
later group appears to be phosphatidylcholine hydrolysis (5). Similar
effects of vasopressin on DAG species in hepatocytes have been
reported (6).
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The physiological relevance of these biphasic responses of
chemically distinct factors is still unclear" It has been suggested
however, that individual chemical species or subgroups of DAG may
have distinct effects on signaling systems. For example, Leach et a1. (7)
have shown that DAG derived from phosphatidylcholine does not
activate PKC, whereas phosphoinositide-derived DAG did activate the
kinase.
DAG species-specific effects have also been reported in adipocytes.
Stralfors has reported DAG species-specific activation of glucose
transport in adipocytes (8). The largest responses (6-fold) were evoked
by incubation with 14:0-14:0, 16:1-16:1 or 18:1-18:1 (the response to
insulin was -20-fold). A non-specific increase in endogenous DAG,
provoked by incubation with PLC, also had a significant, but lower,
effect on glucose transport (-3-fold). This is consistent with the effect
of PLC on glucose transport in muscle (3, 9).
These data support the hypothesis that insulin increases glucose
transport by changing the relative concentration of individual DAG
species in muscle. The goals of the work described in this section were
to separate, identify, and measure the effect of insulin on DAG species
in muscle. The species were separated and quantitated by gas
chromatography. The fatty acid composition of the major species was
identified by comparing the gas chromatography retention times of the
unknowns with those of standards and by using mass spectrometry to
verify

the

molecular

weights
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of

each

DAG

species.

MATERIALS AND METHODS

Animals

Male Wistar rats, 50-80 g (Charles River Laboratories,

Wilmington, MA), were studied after an overnight fast.
Muscle

Incubations

Rats were decapitated and the two

hemidiaphragms along with adjacent ribs were rapidly dissected. Each
hemidiaphragm was incubated individually in Dulbecco's Modified
Eagle's medium (DMEM) supplemented with 0.1% bovine serum
albumin (BSA) with additions as indicated. All incubations were at pH
7 . 4, 37 oC, in media preequilibrated and continuously gassed with 95%
°2-5% C02 in a rotating shaker water bath. After incubation, muscles
were rapidly cut from the rib cage and frozen in liquid nitrogen.
Lipid Extraction.

The frozen muscles were ground to a powder

with a mortar and pestle. The powdered tissue was further disrupted
and the lipids were extracted by homogenization with a Polytron tissue
homogenizer in 5 mL of chloroform-methanol (1:2, vol/vol). To separate
the phases equal volumes of chloroform and water (1.6 mL) were
added. The aqueous phase was washed twice with chloroform and the
organic phases were pooled and dried under a stream ofN2 .
DAG extraction and deriyatization

A known amount of DAG

standard (5 mg of 18:0-20:40)6), was added to the lipid extract to
correct extraction efficiency and for use as a retention time standard.
The anti-oxidant BHT was added to maintain the native unsaturation
state of DAG fatty acyl groups . The DAG fraction of the lipid extract
was separated by TLC. The DAG band (identified by co-migration with
a standard) was scraped from the plate and the lipid was extracted
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from the silica with chloroform-methanol (2: 1, vol:vol). The dried
extract was derivatized to tert-butyldimethylsilyl-DAG by incubation
with tert-butydimethylchlorosilane reagent for 10 min at 80 oC. The
BDMS-DAG product was extracted out of the derivatization solvent
and dried under a stream of N 2.
Gas Chromatollrnphy-Flame Ionization detection The procedure for
separating DAG species was reported by Myher et al. (10) and modified
by Pessin and Raben (5). The derivatized lipids were dissolved in 10 J..lL
of hexane and a 1 J.lL aliquot was injected into a 15m X 0.32m.m (inner
diameter) fused silica capillary column with SP-2380 stationary phase.
The carrier gas was helium. Upon injection, the temperature of the
column oven was 40 0 C, which was maintained for 0 . 5 min . The
temperature was increased to 250 °C at the rate of 30 °C/min. The
temperature was held at 250 °C and the DAG species were eluted
during this isothermal period . Material eluting from the column was
detected by a flame ionization detector maintained at 300 °C . The FID
signal was plotted and integrated. The relative retention time (Tr) of
each peak was determined by dividing its absolute retention time by
the retention time of the 18:0-20:40)6 internal standard. For
measurements of the relative mass of each species, the area under
each peak was normalized to that of the added standard and expressed
per gram of muscle.
GC-Mass spectrometry DAG species were derivatized and the GC
parameters for species separation were as described for GC-FID.
Compounds eluting from the column were detected by a Hewlett
Packard 5780 mass selective detector. To increase sensitivity in the
high mass range (Mr

= 650-700), the detector was run in the selected88

ion monitoring m.ode. Data were collected and stored on a Hewlett
Packard 2000 series Chem.station computer. The data are reported as
:molecular weight and retention time in tabular form. Relative
retention ti:mes of compounds were calculated by co:mparison to the
BHTpeak.
Data Presentation: Means ± SE are shown. Statistical analysis of
differences between means was by Student's t test or by paired t test
where indicated.
Materials Monoco:mponent crystalline pork insulin was a gift from
Dr. Ronald Chance, Eli Lilly Research Laboratories (Indianapolis.

I~r).

DAG species standards were from Serdary Research Laboratories
(London, Ontario, Canada) and stored in solvent as supplied (hexane
or chloroform) under N2 at -20 DC. SP-2380 gas chromatography
columns were from Supelco (Bellefonte, P A). GC-grade hexane,
chloroform and methanol were from EM Science (Gibbstown, NJ). tertButyldim.ethylchlorosilane-imidazole reagent was from Alltech
(Deerfield, IL). All other reagents were purchased from previously
identified sources (3).
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RESULTS
To examine whether insulin selectively increases the concentration
of an individual DAG species, we separated and identified the major
DAG species in rat diaphragms. Although individual fatty acids found
in DAGs isolated from hindlimb muscle have been reported (11) the
intact DAG species from muscle have not been identified. The identity
of these species was determined by gas chromatography with either a
flame ionization detector (GC-FID) or with a mass selective detector
(GC-MS) as described in Methods. The DAG fraction separated into 5
peaks on GC-FID, designated A-E in Table 1 and on the sample GCFID chromatogram shown in Fig 3. The relative retention times (Trs)
of the five species were very consistent (standard deviation < 0.5%).
As shown in Table 1, three of the five species (A, C, and D) were
identified by comparing their Trs with those of standards. Species B
was tentatively identified by using the extensive list of standards
published by Pessin and Raben (5) and by Myher and Kuksis (12).
They show that 16:0-18:1ro7 elutes at 1.02-1.03 times the Tr of 16:018:1009. This is the same proportion found between species A and B.
The identity of species A, C, and D was verified by GC-MS. They
eluted with retention times similar or identical to those of known
standards (Table 1). Species E was identified by the co-elution of the
M-57 ion with fragments of molecular weights corresponding to both
the carbonyl form of 18:1 and 18:2 fatty acids (Rl CO and R2CO,
respectively) and to the acid form bound to the glycerol moiety
(R 1 CO+74 and R2CO+74). Although the position of the fatty acids on
the glycerol was not determined by this method, a DAG species with
the less saturated fatty acid at the Cl position would be very unusual.
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To assess the adequacy of the GC-FID to detect changes in the
content of individual DAG species, diaphragm muscle was incubated
with PLC as a positive control. Each species increased significantly in
response to PLC (Fig. 2). To study the effects of insulin on the relative
abundance of each species, muscles were incubated without or with
insulin for 5, 10, or 20 min and species were quantified by GC-FID. No
species increased significantly during 5 min exposure to insulin
(Fig.3a). At 10 min (Fig 3b), species D and E increased significantly.
After 20 min (Fig. 3c) species A, B, D, and E were significantly
increased. While it is possible that insulin induces changes below the
sensitivity of the assay (coefficient of variation approx. 30%) these data
indicate that no species or subgroup of DAG accounts for most of the
insulin-stimulated increase in total DAG content. Furthermore, our
data do not support a DAG species-specific activation of glucose
transport since no species was increased within 5 min after insulin

exposure.
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DISCUSSION

We have found 5 DAG species in muscle. Although Pessin and
Raben identified 25 species in fibroblasts (5), Cleland et al. identified
only three fatty acids (16:0, 18:0 and 20:4(06) in a muscle DAG fraction
(11). The first two species were identified in peaks A and B (16:0) and
C and D (18:0), respectively. In addition 18:10)9 was identified in peaks
A and C, 18:1ro7 in peak Band 18:2ro6 in peak D. However,
arachidonic acid was not identified in any of the 5 major DAG species
isolated. The differences in DAG composition may reflect, in part,
differences in the fat composition of the diets. Alternatively,
arachidonic acid may be present in minor DAG species which were not
identified by GC-FID. Furthermore, hindlimb and diaphragm DAG
species may have unequal composition. We also did not detect any of
the species that have been shown to stimulate glucose transport in
adipocytes in vitro (8).
Insulin increases DAG mass after 10 and 20 min, but not before
(Chapter 2 and (3) ). Glucose transport, however, was activated by
insulin within 2 . 5 min (13).

In the current report, no species was

found to increase with less than 10 min of exposure to insulin. The
time course of insulin's effect on DAG species reflects the overall
response of DAG content. The possibility exists that one or a few DAG
species increase transiently as insulin diffuses to each muscle cell
layer. However, since only the total DAG in a muscle sample can be
measured, such changes are not detectable.
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There have been several reports of a low molecular weight, heatstable glycosylphosphatidyl inositol, released from a 14:0-14:0 lipid
anchor in hepatocytes in response to insulin (reviewed in (14)). This
hydrophilic headgroup is a putative mediator of insulin action.
Whether PKC activation by free 14:0-14:0 DAG is part of insulin signal
transduction in these cells is unknown. There was no evidence for a
14:0-14:0 species in the DAG species analysis. However, this species is
hypothesized to be a trace constituent of membranes and may be
present in quantities below the level of sensitivity of our instruments.
Insulin provoked increases only in the DAG species found in basal
muscle; no insulin-dependent species were detected.
In conclusion, the data presented in this chapter suggest that
insulin signal transduction pathways in muscle do not include
increases in chemically-defined subgroups of DAG. Whether transient,
specific subcellular pools (locally high concentrations) of DAG are
increased by insulin is unknown.
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Table 3-1 Identification of muscle DAG species by gas chromatography.

Peak

GC-FID
Tr

GC-MS
Tr

Ions

Species

M-57

16:0-18: 1009

A

0.575*

3.8*

B

0.588

NS

C

0.732*

3.05*

M-57

18:0-18:1009

D

0.765*

4.26*

M-57

18:0-18:2006

E

0.800

4.35

M-57, A,B,C,D

18:1-18:2

16:0-18: 1007

Total lipids were extracted from rat skeletal muscle, DAG was
separated by TLC and derivatized as described in Methods. DAG
species were then separated by injection onto a GC column. DAG
standards were treated similarly. The relative retention time (Tr) of
each peak was derived by comparison to an internal standard. NS, not
separated. *, identified by co-elution with DAG standards. For
explanation of the ions used to identify species E see Results. A=R1CO,

B=R2CO, C=R1CO+74, D=R2CO+74
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Figure . 3-1 Gas chromatogram of muscle DAG. Hemidiaphragm
muscle was powdered in liquid nitrogen and extracted in chloroform
and methanol as described in METHODS. The DAG fraction was
isolated by thin-layer chromatography and derivatized with tbutyldimethylchlorosilane. The butyldimethylsilyl-DAG was injected
onto an SP.. 2380 column. The elution of compounds was detected by a
flame ionization detector. Peaks eluting before 15 min were found in
blank runs. A DAG standard (ST; 18:0-20:4) was added at the time of
muscle extraction. The five peaks consistently found in muscle DAG
fractions have been labeled A-E with the retention times in
parentheses.
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Figure. 3. . 2 Effect of PLC on the relative mass of the DAG species
in hemidiaphragm muscle. Hemidiaphragms were preincubated 30
min in DMEM without additions and then transferred to identical
media without (open bars) or with PLC (0.5 U/mL; filled bars) for 30
min. Muscles were frozen, lipids were extracted and DAG species A, B,

C, D, and E were quantitated as described in Materials and Methods.
The data are means + SE of DAG expressed as relative units/g muscle.

All species increased significantly in response to PLC, p < 0.05.
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Figure. 3-3 Time course of insulin effects on DAG species in diaphragm.
Diaphragm muscle was preincubated 20 min in basal medium and then
transferred to medium without (filled bars) or with (open bars) 60 nM insulin
for 5 (a), 10 (b), or 20 (c) min. The muscles were frozen and the DAG species
(bars A-E) were quantitated by GC-FID, as described in methods. The data
are the means + SE in relative units from at least 6 observations. Relative
units ofDAG species were derived from the area under each chromatographic
peak normalized to that of the standard and expressed per g of muscle. *,
Insulin < Basal, p < 0.05.
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Cbapter4
What is the source of the insulin-stimulated increment in DAG
mass in rat skeletal muscle?

Portions of this chapter have been submitted for publication to The American
Journal of Physiology.

INTRODUCTION

Insulin receptor-activated signal transduction mechanisms are
difficult to study because the hormone regulates such diverse aspects
of metabolism. This renders it difficult to discriminate between
downstream products of insulin-activated pathways and authentic
second messengers. Therefore, an important problem in defining the
role of DAG in insulin signaling is to understand its metabolic source.
Of the several possible sources of DAG which are described in
Chapter 1, those which are most likely to be involved in muscle include
PLC-catalyzed hydrolysis of membrane phospholipids and de novo
synthesis. This assertion is based on the following evidence.
Insulin promotes the release of [3H]phosphocholine

from

[3H]phosphatidylcholine-Iabeled BC3H-l myocytes (1). That this effect
is specific for phosphatidylcholine was shown by similar labeling
studies of phosphatidylinositol hydrolysis (2-4). Phosphatidylcholine
can be hydrolyzed to DAG directly by phospholipase C or by the
sequential action of phospholipase D and phosphatidic acid
phosphatase (reviewed in (5». The products of these reactions are
phosphocholine and choline, respectively. Therefore, to examine
whether insulin stimulates the hydrolysis of phosphatidylcholine by
either of these mechanisms the effect of insulin on the diaphragm
content of phosphocholine and choline was measured.
Insulin promotes lipid synthesis (e.g., by activating glycerol-3phosphate acyltransferase, (6». Furthermore, the synthetic precursors
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of lipid synthesis are metabolites of glucose. Since diacylglycerol is a
branch point intermediate in lipid metabolism it appears reasonable
that insulin should increase DAG mass. However, ifDAG is a mediator
of insulin signaling it would be expected to increase specifically in
response to insulin and not simply as a general response to insulinstimulated glucose flux. Therefore to examine the effects of insulin on
DAG synthesis we have measured the flux of glucose carbon into DAG
and other lipids as markers of lipid metabolism as well as the flux into
the major pathways of glucose utilization (e.g., glycogen synthesis and
glycolysis).
The data presented in earlier chapters suggest that DAG is not the
primary mediator of insulin-stimulated glucose transport in skeletal
muscle. However, evidence from several reports (7-10) does support the
notion that elevated DAG content stimulates glucose transport in
insulin-independent pathways. Work in our lab (11) and others (12)
has shown that okadaic acid (OKA; a cell permeant inhibitor of protein
phosphatase types I and IIA) stimulates glucose transport in muscle.
Tanti et ale also showed that OKA does not activate the insulin
receptor (12). It is possible that OKA-stimulated glucose transport is
mediated by changes in DAG mass. Therefore, the effect of OKA on
DAG content in muscle was measured. Also, to determine whether
OKA stimulates DAG through a phospholipase catalyzed mechanism
or through increased glycolytic intermediates, the flux of glucose
carbon into DAG was measured.
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MATERIALS AND METHODS
Animals

Male Wistar BR rats 50-80 g, (Charles River

Laboratories, Wilmington, MA) were studied after an overnight fast.
Muscle

Incubations

Rats were decapitated and the two

hemidiaphragms along with adjacent ribs were rapidly dissected.
Hemidiaphragms or quarter diaphragms (as indicated) were incubated
individually in Dulbecco's Modified Eagle's medium (DMEM, 5.6 mM
glucose, supplemented with 0.1% bovine serum albumin) and with
additions as indicated. All incubations were at pH 7.4, 37 oC, in media
equilibrated and continuously gassed with 95% °2-5% C02 in a
rotating shaker water bath.
In OKA experiments, hemidiaphragms were incubated in DMEM
without or with OKA at the concentrations indicated for 50 min. OKA
stock solutions were prepared in dimethyl sulfoxide; media not
containing these compounds were supplemented with equal
concentrations of the solvent, which never exceeded 0.4% and did not
affect the metabolic parameters measured (data not shown).
Glucose Transport Glucose-free media:

Hemidiaphragms were

preincubated in BSS (supplemented with 2 mM pyruvate) for 30 min
without or with insulin (60 nM). Transport was measured by
transferring muscles to identical media supplemented with 5 mM 2[1,2- 3 H]deoxyglucose (2-DG; 0.5 J..lCi/ml) and 0.1 roM [U_14C]sucrose

(0.1 J.1Ci/ml; included as an extracellular space marker) for 15 min as
previously described (10). The muscles were then dissolved in 0.5 rol of
1 N NaOH and neutralized with 2 N HCI for quantitation by liquid
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scintillation spectrometry. Glucose-containing media: Hemidiaphragms
were preincubated for 30 min in DMEM (5.6 mM glucose) without or
with insulin (60 nM). 2-DG transport was measured by transferring
muscles to identical media supplemented with tracer 2-[1,2- 3 H]DG (0.5
J.,lCi/ml) and 0.1 mM [U_ 14 C]sucrose (0.1 J,.lCilml) for 15 min. Transport
of 2-DG was calculated after correcting for radioactivity in the
extracellular space, and normalized to the weight of the tissue. The
calculations are based on the concentrations of 2-DG and glucose,
respectively, in the media and assume that 2-DG and glucose have
equal affinity for glucose transporters (13).
Quantitation of DAG mass

DAG extracted from muscle was

measured by the DAG kinase assay (14) with modifications as
described (15).
Lipid labeling and glucose utilization

Hemidiaphragms were

preincubated 20 min in basal medium. The tissue was then moved to
vials of fresh medium containing 3 JlCi/ml of [U_ 14 C]glucose and 1
JlCilml of [5- 3 H]glucose without or with 60 nM insulin. After 10 min,
the muscles were removed from the medium, frozen in liquid N 2 , and
rapidly cut into two segments. One segment was used for subsequent
extraction of lipids (as described previously). The other segment was
dissolved in 30% KOH (wt/vol) to measure the incorporation of label
into glycogen as described in Method 2 by Burant et ale (16). The DAG
and triacylglycerol (TAG) fractions were separated from the total lipid
extract by thin layer chromatography on silica gel 60 plates developed
in petroleum ether:ethyl ether (1:1, v/v). The DAG and TAG bands
were identified by co-migration with authentic standards. The spots
were scraped from the plate and the radioactivity was measured by
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liquid scintillation spectrometry_

Glycolysis was measured by the
incorporation of 3H into [3H]H20 from [5- 3 H]glucose. [3H]H20 was
separated from unreacted [5- 3H]glucose in the incubation media by ion
exchange chromatography and quantified (17).
OKA effects on elucose flux in muscle Quarter or hemidiaphragm

muscles were incubated in DMEM supplemented with 3 J.lCilmL of [U14C]glucose and 1 J,!CilmL of [5- 3 H]glucose without or with OKA (1 J,!M)
for 50 min. Glucose flux was measured as described above.
The moles of medium glucose incorporated into different fractions
were calculated from the specific activity of medium glucose and
normalized to tissue weight.
Choline and Phosphocholine assay

Diaphragms were incubated

and extracted as described previously. In this assay the aqueous phase,
instead of the organic, was taken. Choline and phosphocholine were
measured by the method of Murray et al. (18). Briefly, the extract was
supplemented with [3H]choline and [14C]phosphocholine to correct for
variability of extraction. Choline and phosphocholine were separated
by differential extraction using the ion-pairing reagent sodium
tetraphenylboron. Phosphocholine was converted to choline using
alkaline phosphatase. The choline extracted by ion-pairing and that
converted from phosphocholine was phosphorylated by incubation with
[y_32p]ATP and cholin"e kinase, then the unreacted [y_32p]ATP was
removed by ion-exchange chromatography. Choline was quantitated by
comparing counts incorporated into phosphocholine to a standard
curve. An example of a choline kinase assay standard curve is shown in
Fig. 1A.
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Materials

aKA was purchased from Kamiya Biomedical Co.

(Thousand Oaks, CA) and from LC Services Corporation (Woburn,
MA). Other reagents were from Sigma (St. Louis, MO) or previously
identified sources (10).
Data Presentation Means ± SE are shown. Statistical analysis of
differences between means was by Student's t test or paired t tests
with a

= 0.05;

when multiple comparisons were made, the overall a

was maintained at 0.05.
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RESULTS
Insulin stimulation of ~lucose flux in

diaphra~

Before examining

DAG labeling by glucose, a study of the effect of glucose in the media
on insulin-stimulated glucose transport and DAG mass was performed.
Insulin increased glucose transport in both glucose-free or glucosecontaining medium (Fig. 2) to similar extents. In contrast, insulin
increased DAG content in rat diaphragms only in glucose-containing
medium (Fig. 3).
Since the insulin-stimulated increase In DAG mass appears to
depend on medium glucose, this suggests that insulin stimulates DAG
synthesis downstream of glucose transport. To test this, diaphragm
muscles were incubated without or with insulin as described in
Methods and lipid labeling and glucose utilization were measured (Fig.
4). Measurement of insulin stimulated glucose transport was most

reproducible when studied in diaphragms attached to adjacent rib cage
(data not shown). Although before incubating muscles, all tissue not
required to maintain the muscle resting length was removed, we
recognize that the small amount of tissue remaining contributes to
basal glycolysis and is also probably not responsive to insulin. Our
results are, however, similar to published values of glycolysis in muscle
(13).

For glucose flux studies, muscles were incubated 10 min in media
supplemented with labeled glucose to allow comparison of the results
to the DAG mass studies described earlier, and because limited 02
diffusion in isolated muscle may result in anoxia during prolonged
incubation (19, 20). However, equilibrium labeling of precursor pools
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was probably not attained during this short incubation period.
Therefore, these experiments do not measure total de novo synthesis.
They do, however, measure the relative response of lipid synthesis to
insulin and other physiological conditions.
Insulin stimulated the labeling of DAG, TAG and total lipids by -3fold and glycogen synthesis - lO-fold (Fig. 4 A, B, C, E; respectively).
The 20-30% apparent increase in glycogen synthesis in insulin treated
muscles did not reach statistical significance, suggesting (Fig. 4 D) that
the insulin effect on lipid synthesis was specific and not simply an
effect of increased glycolytic intermediates. Although the bone and
other non-muscle tissue incubated with the diaphragm-on-ribs
preparations would partially mask the insulin effect on glycolysis, it
seems unlikely that a response similar to that of lipid labeling would
be masked by the relatively small amount of tissue.
Effect of insulin on choline and phosVhocholine content of
diaphra~m

To assess the adequacy of the analytical methods in

skeletal muscle, the concentration of choline and phosphocholine were
measured in rat hemidiaphragms after incubation without or with
phospholipase C (PLC). Phosphocholine increased 87% compared to
basal; no change in choline content was observed (Fig. 1 B). The
percent phosphocholine increase produced by PLC was similar to its
effect on the DAG mass in muscle (10). The effect of insulin on choline
and phosphocholine levels was then measured. Under conditions in
which insulin increased DAG mass there was no increase in either of
these compounds (Fig. 5). Therefore, hydrolysis of the predominant
phospholipid in muscle apparently does not account for the insulinstimulated increase in DAG.
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Okadaic acid

OKA stimulates glucose transport in muscle,

although a maximal response requires 45-50 min (11, 12). To measure
the response of DAG to OKA, we incubated muscle for 50 min without
or with the compound at the concentrations indicated and measured
the total mass of DAG. OKA at 0.5 and 1 f.1M increased DAG mass in
diaphragm to an extent similar to insulin (Table 1). However, also like
insulin, a higher concentration of OKA (500 nM) was required for the
DAG response, than for half-maximal stimulation of glucose transport
(100 nM).

To determine whether OKA increases the de novo synthesis of DAG,
we performed labeling studies similar to those described for insulin
t

(Fig. 4). The results of a dose response study are shown in Fig. 6, OKA
(lmM) increased the labeling of DAG, TAG and total lipids. The effect

of OKA appears to be relatively specific for lipids because glycolysis
and glycogen synthesis were not increased.
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DISCUSSION

The data described in this chapter suggest that the insulinmediated increase in DAG mass is downstream of insulin's stimulation
of glucose transport. First, glucose was required for the insulin effect
on DAG content in diaphragm. However, as shown in Chapter 2 of this
dissertation, insulin-increased DAG mass in soleus muscle did not
require incubation in glucose-containing medium. Each of these
observations have been confirmed by Ishizuka et ale (21). Therefore,
this effect may be muscle-type specific. The glycogen stores in soleus
muscle are -2.5-fold greater than in diaphragm (16, 22) the insulinmediated increase in DAG in solei incubated without glucose may
reflect the increased availability of endogenous glucose.
Second, we found that insulin promoted a >3-fold Increase In
glucose incorporation into DAG, TAG and total lipids. Furthermore,
the insulin-stimulated increase in glucose flux into lipids was also
several-fold greater than the stimulation of glycolysis, suggesting that
insulin activates lipid synthetic enzymes distal to glycolysis. This is
consistent with a report from Augert et al., showing that insulin
activates lipid synthesis enzymes downstream of glycerol-3-phosphate
acyltransferase in adipocytes (23). In contrast, Farese's group found
little insulin-stimulated incorporation of glucose carbon into DAG in
soleus muscle under conditions where insulin increased both glucose
transport and the incorporation of glycerol into DAG (24). The
apparent discrepancy may reflect differences in the incubation
conditions.

In the study by Farese's group (24), soleus muscles of 100-

150g rats were incubated; the thickness of such muscles may limit 02
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diffusion resulting in an anoxic core (19, 20) which could impede lipid
synthesis.
Heydrick et al. recently reported that, in soleus muscle from 24 hr
sham-denervated rats, insulin increased glucose flux into lipids -100%
over basal while glycolytic flux increased -75% (13). This appears to be
inconsistent with our observation that insulin increases lipid labeling
much more than glycolysis (Fig. 4).

This difference may reflect, in

part, the effects of post-surgical levels of counter-regulatory hormones
on lipid synthetic enzymes. For example, epinephrine has been shown
to inhibit glycerol-3-phosphate acyltransferase in cardiac myocytes
(25).

The role of DAG/PKC signaling In insulin action remains
controversial. Farese's group reported that insulin stimulates both
PKC translocation to the plasma membrane and the phosphorylation of
endogenous PKC marker substrates in skeletal muscle (26). PKC
activation may serve as a positive modulator of insulin action e.g., by
increasing glucose transport, and/or as a negative downstream
modulator involved in the termination of insulin's signal. Indeed, both
effects may be promoted through the phosphorylation of separate PKC
substrates with disparate temporal responses. The role of DAGIPKC in
stimulating muscle glucose transport is supported, for example, by
reports showing that PLC, an enzyme which increases endogenous
DAG levels, stimulates glucose transport in muscle (7, 10). However,
the effect of PLC on glucose transport has been suggested to mimic an
exercise / anoxia stimulated pathway rather than that regulated by
insulin (7). On the other hand, DAG/PKC may act to limit the
physiological response to insulin stimulation through effects on the
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insulin receptor itself. SerIThr phosphorylation of the insulin receptor
inhibits its tyrosine kinase activity (27). Consistent with this, Chin et
al. (28) have recently shown that several PKC isozymes in 3T3-Ll
adipocytes inhibit insulin-activated phosphorylation of an endogenous
protein (phosphatidylinositol 3-kinase). Furthermore, PKC activation
inhibits glycogen synthase (29). The data presented here do not
indicate whether PKC amplifies or limits the metabolic responses to
insulin. However, since the insulin-mediated increase in muscle DAG
content appears to be distal to glucose transport stimulation, with
respect to glucose metabolism the latter hypothesis seems the more
likely.
Phosphatidylcholine is the most abundant phospholipid in muscle
membranes (9). Its hydrolysis has been shown to be a source of agoniststimulated

DAG.

In

several

models,

the

hydrolysis

of

phosphatidylcholine is a delayed and sustained response, following the
more immediate and transient hydrolysis of phosphatidylinositol
phosphates (PIP's) (for a review see (5». Several studies have shown
that insulin does not stimulate the hydrolysis of PIP's in muscle or
muscle cell lines (3).

In membranes isolated from fibroblasts over-

expressing human insulin receptors and fat cell homogenates preexposure of the cells to insulin increased PLC activity toward
phosphatidylinositol 4-phosphate (30-32). No similar effect has been
described in striated muscle. In this report we show that the products
of phospholipase

C

or D

cleavage

of phosphatidylcholine,

phosphocholine or choline, respectively, do not increase in response to
insulin. Although these metabolites may be used along with DAG to
resynthesize phosphatidylcholine in the de novo synthesis (Kennedy)
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pathway, Cleland has shown that DAG levels stimulated by
electrically-induced muscle contractions remain elevated for 30 min or
more

(9). This would be inconsistent with the removal of

phosphocholine by the phosphatidylcholine synthesis pathway.
Although other sources of DAG, such as lipase-catalyzed hydrolysis
of TAG are possible, they seem unlikely. DAG from this source is not
detected by the DAG kinase assay and insulin inhibits triglyceride
lipase and activates triglyceride synthesis.
Initially, we speculated that the OKA effect on glucose transport
may be mediated by increased DAG. The results in Table 1 indicate
that indeed, OKA increases the DAG content of diaphragm muscle.
However, the dose required (0.5 mM) was five-fold higher than that
required for half-maximal stimulation of glucose transport in rat
hemidiaphragms and 20-fold higher than the minimal dose which
significantly stimulates transport (11). This dose response suggests
that OKA-stimulated glucose transport is not mediated through
increased DAG content. Reversible phosphorylation has been
suggested to modulate the activity of regulatory enzymes in lipid
synthesis (33), which may mediate OKA's effects on muscle DAG
content.
The increase in muscle DAG mass in response to OKA appears to be
inconsistent with results reported by Hatch et al (34). They found that
OKA inhibits the increase in DAG found in control cultured
hepatocytes. They suggest that this effect of OKA is consistent with
two previous reports, one showing that OKA inhibits acetyl-CoA
carboxylase (35) thereby reducing the availability of fatty acids for de
novo synthesis and the other showing that OKA inhibits PA
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phosphatase (36) and thus the converSIon of PA to DAG. The
discrepancy between these results in hepatocytes and those in muscle
presented here, may be explained by the metabolic differences between
the two tissues. Liver is a major site of fatty acid synthesis and
changes in acetyl-CoA carboxylase has significant effects on lipid
metabolism in hepatocytes. In contrast, muscle has little capacity to
synthesize fatty acids (37). However, these results are similar to those
in fat cells, where glucose flux into total lipids increased in response to

OKA (12).

Also, the OKA-induced increase in muscle DAG content

may be due to inhibition of cytidylyltransferase (34) and a subsequent
increase in precursors of phosphatidylcholine synthesis, the most
proximal of which is DAG.
In conclusion, the data suggest that insulin-induced increases in
muscle DAG content likely reflect downstream effects of changes in
glucose transport and metabolism.
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Table 4-1 Effect of okadaic acid on 1,2-diacylglycerol content in muscle

OKA,nM

DAG

Increase

(nmollg)

(% of basal)

a

347+/-22.8

100

362+/-26.7

a

319+/-24.8

500

388+/-26.4

a

361+/-69.4

1000

525+/-128.6

(n)

4.3+/- 10.0

(4)

23.6+/-8.2a

(8)

43.5+/-11.8a

(4)

Hemidiaphragms attached to ribs were incubated in basal medium for 50
min, one hemidiaphragm of each rat without and the other with okadaic acid
(OKA) at the concentrations indicated. After incubation, muscles were frozen
and DAG was measured by the kinase assay. a, significant increase, p < 0.05,
Student's t test.
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Figure. 4-1 Assessment of choline kinase assay. A. Representitive
standard curve. Each point is the mean ± SE of 3 determinations. B.
Effect of PLC on diaphragm choline and phospho choline content. The
concentrations of choline and phospho choline were measured in rat
hemidiaphragms after 30 min incubation without (open bars) or with
PLC, (0.5 U/ml; solid bars) in DMEM. *, PLC > Basal, p < 0.05, n
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Figure. 4-2 Effect of insulin on glucose uptake into diaphragm
incubated in media without or with glucose. Hemidiaphragm muscles
were incubated in either BSS (supplemented with 2 mM pyruvate,
glucose-free) or in DMEM (5.6 mM glucose) without (open bars) or with
insulin (60 nM; filled bars). Glucose transport was measured as
described in Methods. *, Insulin> Basal, p < 0.05, Student's t test, n =
6.
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Figure. 4-3 Effect of insulin on DAG mass in muscle incubated in
BSS or DMEM. Hemidiaphragm muscles were preincubated 30 min in
the either media without additions then transferred to identical media
without (open bars) or with insulin (60 nM; filled bars). Mter an
additional 10 min incubation, the muscles were rapidly cut from the
associated rib cage and frozen. DAG was extracted and measured as
described in Methods. The data are expressed as means + SE of nmol
DAG/g muscle, n = 6. *, Insulin> Basal, p < 0.05, Students t test.
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Figure. 4-4 Effect of insulin on [3H]glucose disposition in muscle.
Hemidiaphragms were incubated in DMEM with [U_ 14C]glucose and
5-[3H]glucose, without (solid bars) or with (open bars) insulin (60 nM)
as described in Methods. After incubation, muscle was rinsed in fresh
medium,

dissected from the ribs, frozen and cut into two

approximately equal pieces; one for lipid studies and the other for
glycogen measurement . DAG (a) and TAG (b) were extracted,
separated by TLC, scraped from the plates and counted. An aliquot of
the lipid extract was saved for measurement of total lipids (c). 3H20
from glycolysis (d) was separated by ion-exchange chromatography
from measured aliquots of the incubation medium and counted. Tissue
saved for glycogen (e) measurements was dissolved, glycogen was
precipitated, washed and counted. Data are expressed as nmol glucose
utilized/g muscle ± SE, n > 6. *, Insulin> Basal, p > 0.05, Students t
test.
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Figure. 4-5

The effect of insulin on muscle choline and

phosphocholine content. Hemidiaphragms were preincubated 30 min in
media without additions. Muscles were then switched to fresh media
without (open bars) or with insulin (60 nM; filled bars) for 10 min. The
tissue was frozen and powdered; choline and phosphocholine were
measured as described in Methods. The results are the means + SE of
11 observations.
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Figure. 4-6 Dose effect of OKA on [U-14C]glucose disposition in
muscle. Quarter diaphragms attached to ribs were incubated in DMEM
supplemented with U-[14C]glucose and 5-[3H]glucose, without (open
bars) or with OKA (at the doses indicated in JlM) for 50 min. Muscles
were then rinsed, cut from the ribs and frozen. Flux of [U-14C]glucose
into DAG (A), TAG (B), total lipids (C), glycolysis (D) and glycogen
synthesis (E) was estimated as described in Methods. Data are
expressed as nmol medium glucose utilized/g muscle ± SE, n
OKA> Basal, p < 0.05 by analysis of variance.
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CHAPTER 5

EFFECT OF INSULIN AND OKADAIC ACID ON DAG MASS IN
DENERVATED DIAPHRAGM

INTRODUCTION
Muscle denervation, which leads to severe insulin resistance of
several pathways, including glucose transport and glycogen synthesis
(1,2) is an easily accessible model of defective insulin signal
transduction. The lesion in denervated muscle is still not understood.
However, it clearly lies distal to insulin receptor activation (1,2),
therefore further study of the defect may help clarify insulin's
signaling mechanisms.
Although evidence from early experiments suggested that DAG was
a positive mediator of insulin action, more recent evidence suggests
that DAG may act as a negative downstream effector in muscle (3).
First, insulin increases DAG after, instead of before, insulin
stimulated glucose transport (Chapter 2). Second, it has been shown
that muscle incubated with PLC and insulin takes up less glucose
than muscle incubated with insulin alone (4). Third, DAG inhibits
insulin receptor tyrosine kinase activity in vitro (5,6).
To test whether insulin resistance of denervated muscle is due to
chronically elevated DAG mass, denervation-mediated changes in
muscle DAG content were examined. Since the insulin resistance of
glucose transport increases from 1 to 3 days post-denervation, both
time points were studied.
OKA increases glucose transport in insulin resistant muscle (7)
similarly to its effect on normal muscle. This suggests that OKA acts
either downstream of the denervation-induced lesion in the insulin
resistant pathway or by a pathway independent of insulin activation.
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Other agents which activate glucose transport through an insulin
receptor-independent mechanism have been shown to increase DAG
mass (e.g., muscle contraction (8) and PLC (4, 9)). This prompted an
investigation into whether OKA increases DAG mass in 3-day
denervated muscle.
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MATERIALS AND METHODS

Male Wistar BR rats 50-80 g, (Charles River

Animals

Laboratories, Wilmington, MA) were studied after an overnight fast.
Diaphra~m

denervation

Rats were anesthetized with Metofane

(Pittman-Moore; Washington Crossing, NJ) and diaphragms were
unilaterally denervated by cutting the phrenic nerve through a
cervical approach. The wounds were closed with surgical clips.
Muscle

Incubations

Rats were decapitated and the two

hemidiaphragms along with adjacent ribs were rapidly dissected.
Hemidiaphragms were cut into two approximately equal portions and
incubated individually in Dulbecco's Modified Eagle's medium
(DMEM, 5.6 mM glucose) supplemented with 0.1% bovine serum
albumin, with additions as indicated. All incubations were at pH 7.4,
37 oC, in media equilibrated and continuously gassed with 95% 02-5%

C02 in a rotating shaker water bath.
Glucose Transport Quarter diaphragm muscles from either control
or denervated hemidiaphragms were incubated without or with
insulin in Gey and Gey's balanced salt solution (10) supplemented
with 0.1% bovine serum albumin. The uptake of2-DG was measured
in a subsequent 15 min assay as described in earlier chapters and in
(9).

Quantitation of DAG mass
measured by the DAG

kinas~

DAG extracted from muscle was
assay (11) with modifications as

described (12).
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Data Presentation

Means ± SE are shown. Statistical analysis of

differences between means was by Student's t test or paired t tests, as
indicated.
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RESULTS

Glucose transport and DAG mass in denervated diaphraem.

The

data in Table 1 verify that the severity of insulin resistance in
diaphragm increases between 1 and 3 days post-denervation. Glucose
transport in 1-day denervated muscle was clearly insulin resistant
(Table 1). Insulin resistance was more pronounced 3-days after
denervation.

Basal glucose transport was slightly, albeit not

significantly greater in denervated muscles than in their nondenervated pairs (Table 1).
To measure the effect of denervation on the basal and insulinstimulated mass of DAG in muscle, quarter diaphragms from either
denervated hemidiaphragms or contralateral intact hemidiaphragms
were incubated without or with insulin and DAG mass was measured
as described in Methods. As shown in Fig. 1 and (9), the basal DAG
mass of 1-day denervated diaphragm was elevated -100% compared to
its contralateral control.

The DAG content of I-day denervated

muscle did not increase in response to insulin, whereas DAG
increased by -30% (p < 0.05) in the comtralateral non-denervated
paIr.

By 3 days, however, the basal DAG mass was similar in

denervated muscles and their non-denervated pairs, but again, only
the intact muscle responded to insulin with an increase in DAG mass.
Basal glucose transport and the basal DAG mass in contralateral
control muscles appeared to be higher on day 3 than on day 1 after
denervation. This may reflect experimental variability, since 1 and 3
day post-operative rats were studied in separate experiments. Mean
basal DAG values in non-operated controls varied between 150 - 300
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nmol/g in different experiments In Chapter 4.

Alternatively, the

stress associated with surgery and, more likely, the increased
workload, may alter basal glucose transport and the basal DAG mass
in muscles.

Nevertheless, irrespective of basal values, insulin

increased DAG in contralateral control muscles similarly to that in
muscles from non-operated rats in Chapter 4.
Effect of OKA on DAG mass and 2"lucose flux in denervated
diaphra"m.

Although OKA (1 JlM) increased glucose transport in 3-

day denervated muscle (7) it had no significant effect on the total mass
of DAG (Table 2).
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DISCUSSION

We originally observed that basal DAG mass was elevated in I-day
denervated diaphragm muscle compared to contralateral control
Illuscle (Fig. 1 and (9». This has been verified by Heydrick et al. in
soleus Illuscles (3). These data were consistent with the hypothesis
that insulin resistance in denervated muscle may be mediated by the
DAG/PKC system.

However, while glucose transport becomes even

less sensitive to insulin 3 days post-denervation, basal DAG mass was
the same as in contralateral controls. Thus, elevated DAG mass is
likely not responsible for the insulin-resistance of glucose transport in
denervated muscle.
Basal glucose transport was slightly higher in denervated muscles
than in their intact pairs (Table 1).

This may reflect increased

expression of the non-insulin responsive glucose transporter isoform
(GLUT-I) which is found mostly in the sarcolemma, and which
increases in hindlimb muscles after denervation (13, 14).
Denervation affects gene expression of muscle proteins such as the
insulin responsive glucose transporter (GLUT 4; (13, 14», voltagesensitive sodium channels (15) and nicotinic acetylcholine receptors
(16). However, decreased expression of GLUT-4 is observed 48-72 h
after denervation, while insulin resistance of glucose transport can be
observed within 6 h (reviewed in (13». Second messenger systems
also appear to be affected by denervation; Heydrick et ale have shown
that concomitant with

increase~

DAG, PKC activity also increased in

I-day denervated muscle (3). Also, Chahine et ale have shown that
cAMP content and cAMP-dependent protein kinase activity increased
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as early as I-day after muscle denervation (17).

None of these

changes, however, correlate well with the onset of insulin resistance.
The changes in gene expression and cAMP/PKA have not been shown
to occur early enough after denervation to account for insulin
resistance and, as described here, the early increase in basal DAG
m.ass was not found in more severely insulin resistant muscle.
OKA has been shown to increase glucose transport in 3-day
denervated muscle (7), however, it had no significant effect on the
total mass of DAG (Table 2) in this model. These data support the
notion, first suggested by the OKA dose response of total DAG mass
described in Chapter 4, that DAG does not mediate OKA-stimulated
glucose transport.
In conclusion, we provide evidence that chronically elevated basal
DAG mass is not required to maintain denervation-induced insulin
resistance of glucose transport.
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Table 5-1
Effect of insulin on 2-deoxyglucose uptake in intact, I-day and 3-day
denervated diaphragm.
INTACT
Basal

DENERVATED

Insulin

Basal

Insulin

1 Day

0.91+/-0.13

3.01+/-0.44a 1.28+/-0.16

2.07+/-0.22 a ,b

3 Day

1.48+/-0.13

3.26+/-0.33a 1.79+/-0.15

1.75+/-0.14b

Hemidiaphragms were cut in half and preincubated 30 min in balanced
salt solution without additions. The muscles were then transferred to
fresh media without or with 0.6 nM insulin for 15 min. 2-Deoxyglucose
C2-DG) uptake was measured in a subsequent 15 min assay as
described in Methods. The data are expressed as the means + SE of79 observations. a, Insulin> Basal, p < 0.05. b, Denervated <
corresponding intact, p < 0.05.
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Table 5-2
Effect of okadaic acid on 1,2-diacylglycerol content in control and
denervated muscle

Muscle

C

D

DAGmass
aKA effect
(runol/g)
(% increase in
DAGmass)

(n)

vehicle

326 + 30.0

36.5 + 12.2

(8)

aKA

441 ± 47.4

vehicle

340 + 40.2

5.6 ± 10.3

(8)

aKA

346 ± 38.2

Addition

Quarter diaphragms from control (C) or 3-day denervated
(D) hemidiaphragms were incubated in DMEM without or

with OKA (1 J,lM) for 50 min. After incubation, muscles
were frozen and DAG was measured as described in
Methods. a, significant increase, p < 0.05, Student's t test.
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Figure. 5-1 Effect of insulin on DAG mass in 1- and 3-day denervated
diaphragm muscles. Intact and denervated quarter diaphragms were
incubated without (open bars) or with insulin (60 nM; filled bars) and DAG
was measured as described in Methods. Data are means ± SE. *, Insulin>
Paired Basal; **, Denervated Basal> Intact Basal, p < 0.05, n
t test.
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=8, Student's
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The goal of the work described in this dissertation was to examine
the role of 1,2-diacylglycerol (DAG) in insulin-stimulated glucose
transport in skeletal muscle. Initially, it was speculated that DAG was a
positive mediator of insulin action.

Therefore, we measured the

response of DAG to insulin and compared those results to the welldescribed effects of insulin on glucose transport.

The data indicated

that while total DAG mass in muscle does increase in response to
insulin in vitro and in vivo, the time course and dose response suggest
that DAG increases as a consequence of insulin-stimulated glucose
transport or insulin-mediated activation of enzymes involved in lipid
synthesis or both, but not as an upstream mediator.
The lack of kinetic correlation between increases in total DAG mass
and the insulin response of glucose transport does not however,
exclude a response by an individual chemical species of DAG.

Data

which support a DAG species-specific mechanism of insulinstimulated glucose transport in adipocytes (1) along with data from our
laboratory which indirectly supported this hypothesis (2) prompted a
study of the response of DAG species to insulin in muscle. Five DAG
species with fatty acid compositions common to the phospholipids of
mammalian

cells

chromatography.

(3)

were

separated

and

identified by

gas

A time course study showed that no species

increased after 5 min exposure to insulin. After 10 min incubation with
insulin all species appeared to increase, two of them increased
significantly. Therefore, the response paralleled that of the total mass
of DAG to insulin.
The well-studied models of DAG-mediated signal transduction
suggest that receptors activate specific phospholipases and consequently
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release DAG by phospholipid hydrolysis. Previous studies in isolated
adipocytes (4) and a myocyte cell line (5) have shown no increase in
phosphatidylinositol hydrolysis in response to insulin.
whether

insulin

action

toward

DAG

is

To study

mediated

by

a

phosphatidylcholine-specific phospholipase, two hydrolytic products,
choline and phosphocholine were measured. Insulin had no effect on
either form of the headgroup. This suggests that phosphatidylcholine
was not hydrolyzed in response to insulin in muscle.
An important caveat which applies to the analytical studies
presented here is that physiologically relevant changes in DAG (either
in total mass or that of a species) may escape detection by the assays
which were applied. The data, however, suggest that DAG is not the
early positive mediator of insulin-stimulated glucose transport.
Insulin did not increase DAG in muscles incubated in glucose-free
media. This suggests that the effect of insulin on DAG mass
novo DAG synthesis from glucose.

refl~cts

de

Lipids in muscle are synthesized

by the esterification of fatty acids to glycerol-3-phosphate (from
glycolysis).

Therefore, to examine whether the effect of insulin on

DAG reflects increased de novo synthesis, we measured the effect of
insulin on glucose flux in muscle.

Indeed, insulin was found to

increase the labeling of DAG as well as that of triacylglycerol and total
lipids in muscles incubated with [U- 14C] glucose. This effect appeared to
be specific; although glucose flux into lipids increased similarly to the
effect of insulin on glucose transport, flux into lipids exceeded that into
glycolysis.

This is consistent with reports showing that insulin

increases the activity of lipid synthetic enzymes (e.g., glycerol-3phosphate acyltransferase; (6».

A continuing interest of this laboratory is the mechanism by which
muscle denervation leads to insulin resistance.

Work from this

laboratory (2) and from others (7) suggested that chronically elevated
levels of DAG may lead to insulin resistance. The apparent response of
DAG mass to insulin downstream of insulin-stimulated glucose
transport was consistent with this hypothesis. However, although basal
DAG mass was elevated in 1-day denervated muscle, there was no
corresponding increase in basal DAG mass in the more severely
insulin resistant 3-day denervated muscle.

Therefore, unless acutely

elevated DAG mass activates a more chronic glucose transport
inhibitory mechanism, the data do not suggest that increased DAG
mass causes the insulin resistance of denervated muscle.
Okadaic acid is a potent inhibitor of protein phosphatases type 1 and
2A.

It has been shown (8) and confirmed in our laboratory (9), that

OKA increases glucose transport in skeletal muscle.
independent of the insulin receptor (8).

The effect is

This prompted an

investigation of the effects of OKA on DAG in muscle.
indicate that DAG does increase in response to OKA.

The data

Furthermore,

glucose flux studies indicate that de novo synthesis of lipids also
increases in response to OKA. The dose of OKA required (0.5 J..lM) to
increase DAG mass was five-fold higher than that required for halfmaximal stimulation of glucose transport in rat hemidiaphragms and
20-fold higher than the minimal dose which significantly stimulates
transport (9). Another discrepancy between the effects of OKA on DAG
and on glucose transport is that }Vhile OKA simulates glucose transport
in denervated muscle, DAG did not increase in denervated muscle in
response to OKA.

Taken together, these data suggest that OKA-
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stimulated glucose transport is not mediated by an increase in DAG
mass.
Cellular responses to insulin range from early (occurring within 5
min exposure to insulin; e.g., glucose transport) to intermediate (5-30
min, e.g., regulation of enzyme activity and translational regulation) to
long term (hours, e.g., transcriptional regulation).

Although the data

presented here do not support a role for DAG as a proximal mediator of
early responses to insulin, the significant increase in DAG mass which
was induced by insulin suggests that DAG may modulate or mediate
the responses of intermediate or long term insulin-regulated pathways.
For example,

since PKC activation inhibits glycogen synthase, DAG

may act as a negative modulator of glycogen synthesis.
Long term effects of insulin which may be mediated or modulated
by DAG include gene expression at the level of transcription.

Two

systems of cis-acting elements and their specific binding by transacting
factors are possible candidates for regulation by DAG due to their
proposed regulation by phosphorylation.

These are TP A response

elements (TREs) which bind the AP-l transcription factor and insulin
response elements (IREs) that are thought to bind IRE binding proteins
(10)
Since IRE binding proteins have not been found in skeletal muscle,
(10) the possible role of the AP-l/TRE system will be described further.
TREs are found in the regulatory domain of genes which are
activated by TPA as well as by agents which activates PKC. These genes
include those for collagenase,

m~tallothionein

IIa and c-jun (11). PKC

is thought to activate transcription at TREs by inducing formation of
stable AP-l

complexes.

AP-l is composed of either jun-fos
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heterodimers or of jun-jun homodimers.

Dimerization has been

shown to be regulated through alterations in the phosphorylation
pattern of jun (11).
No evidence for AP-l regulated gene expression in muscle has been
reported. Therefore, to investigate a relationship between increased
DAG content and transcriptional regulation through AP-l/TRE
interactions, insulin responsive genes that contain TREs in their
regulatory domains must be identified.

Then, transcription of these

genes must be shown to be increased in response to treatment with
PLC. Strong evidence for this hypothesis would include cotransfection
of a muscle cell line with a reporter gene (e.g., chloramphenicol
acetyltransferase, CAT) driven by a regulatory sequence of the proposed
insulin-responsive gene, along with a vector that expresses PLC in a
regulatable fashion (e.g., via the lac activator protein system of Labow
et a1. (12».

CAT expression under conditions which promote PLC

expression would indicate that DAG induces transcription from the
proposed insulin regulated sequence.

In conclusion, the data presented here do not support the idea that
DAG is a mediator of insulin-stimulated glucose tranport is skeletal
muscle. A possible role for chronically elevated DAG as an inhibitor of
insulin-stimulated glucose transport in insulin resistant muscle is also
not supported by the data. However, since the results show that DAG
increases downstream of insulin-stimulated glucose transport, the
increment in DAG content may act as a signal which limits the
physiological response of muscle to insulin.
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